IIS: NDC Lookup Crosswalk
Email Updates
This webpage is designed as a lookup table where the Unit of Use and Unit of Sale NDC are mapped to each other. A few vaccines are packaged with two component vaccines. Each component vaccine of a multiple component vaccine will have a unique NDC which also differs from the NDC of the unit of sale. Pentacel is an example. This means that there will be two rows linking the unit of use to unit of sale.
Global Trade Identification Numbers (GTINs) are provided as a proxy indicator that the vaccine is 2D barcoded. Note that we have recently learned that some of the GTINs in this table are inaccurate due to variations in the GTIN formats used by manufacturers. Specifically, some vaccine manufacturers are populating the first digit of the GTIN as a packaging level Indicator. Users are advised to use these GTIN values with caution until CDC can verify accuracy with the vaccine manufacturers.
A new expanded version of the NDC Lookup Crosswalk table is now available for download only. This new NDC Consolidated Crosswalk file provides additional field and code details and adds CPT codes associated to NDC Units of Use
Sort Table by Column: Simply click on the column heading to sort the table accordingly.
The columns are defined after the table.
Sale NDC11 | Sale Proprietary Name | Sale Labeler | Start Date | End Date | Sale GTIN | Sale Last Update | Use NDC11 | No Use NDC | Use GTIN | Use Last Update | CVX Code | CVX Description | MVX Code |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
00005-0100-02 | Trumenba | Wyeth Pharmaceutical Division of Wyeth Holdings LLC | 11/5/2014 | 00300050100027 | 11/22/2019 | 00005-0100-01 | False | 00300050100010 | 2/1/2023 | 162 | meningococcal B, recombinant | PFR | |
00005-0100-05 | Trumenba | Wyeth Pharmaceutical Division of Wyeth Holdings LLC | 11/5/2014 | 00300050100058 | 11/22/2019 | 00005-0100-01 | False | 00300050100010 | 2/1/2023 | 162 | meningococcal B, recombinant | PFR | |
00005-0100-10 | Trumenba | Wyeth Pharmaceutical Division of Wyeth Holdings LLC | 11/5/2014 | 00300050100102 | 11/22/2019 | 00005-0100-01 | False | 00300050100010 | 2/1/2023 | 162 | meningococcal B, recombinant | PFR | |
00005-1970-50 | Prevnar | Wyeth Pharmaceutical Division of Wyeth Holdings Corporation, a subsidiary of Pfizer Inc. | 3/1/2000 | 12/31/2011 | 5/30/2018 | 00005-1970-49 | False | 5/30/2018 | 100 | pneumococcal conjugate PCV 7 | WAL | ||
00005-1971-02 | PREVNAR 13 | Wyeth Pharmaceutical Division of Wyeth Holdings LLC | 3/12/2010 | 00300051971022 | 8/6/2024 | 00005-1971-01 | False | 00300051971015 | 8/6/2024 | 133 | Pneumococcal conjugate PCV 13 | PFR | |
00005-1971-04 | PREVNAR 13 | Wyeth Pharmaceutical Division of Wyeth Holdings LLC, a subsidiary of Pfizer Inc. | 3/12/2010 | 7/29/2016 | 2/3/2023 | 00005-1971-01 | False | 00300051971015 | 8/6/2024 | 133 | Pneumococcal conjugate PCV 13 | PFR | |
00005-1971-05 | PREVNAR 13 | Wyeth Pharmaceutical Division of Wyeth Holdings LLC | 3/12/2010 | 00300051971053 | 8/6/2024 | 00005-1971-01 | False | 00300051971015 | 8/6/2024 | 133 | Pneumococcal conjugate PCV 13 | PFR | |
00005-2000-02 | Prevnar 20 | Wyeth Pharmaceutical Division of Wyeth Holdings LLC | 8/10/2021 | 00300052000028 | 2/13/2024 | 00005-2000-01 | False | 10300052000018 | 2/13/2024 | 216 | Pneumococcal conjugate PCV20, polysaccharide CRM197 conjugate, adjuvant, PF | PFR | |
00005-2000-10 | Prevnar 20 | Wyeth Pharmaceutical Division of Wyeth Holdings LLC | 8/10/2021 | 00300052000103 | 2/13/2024 | 00005-2000-01 | False | 10300052000018 | 2/13/2024 | 216 | Pneumococcal conjugate PCV20, polysaccharide CRM197 conjugate, adjuvant, PF | PFR | |
00006-4045-00 | GARDASIL | Merck Sharp & Dohme LLC | 6/8/2006 | 7/5/2022 | 00006-4045-01 | False | 00300064045017 | 2/1/2023 | 62 | HPV, quadrivalent | MSD | ||
00006-4045-41 | GARDASIL | Merck Sharp & Dohme LLC | 6/8/2006 | 7/5/2022 | 00006-4045-01 | False | 00300064045017 | 2/1/2023 | 62 | HPV, quadrivalent | MSD | ||
00006-4047-20 | RotaTeq | Merck Sharp & Dohme LLC | 2/3/2006 | 00300064047202 | 5/17/2022 | 00006-4047-02 | False | 2/1/2023 | 116 | rotavirus, pentavalent | MSD | ||
00006-4047-20 | RotaTeq | Merck Sharp & Dohme LLC | 2/3/2006 | 00300064047202 | 5/17/2022 | 00006-4047-01 | False | 00300064047011 | 2/1/2023 | 116 | rotavirus, pentavalent | MSD | |
00006-4047-41 | RotaTeq | Merck Sharp & Dohme LLC | 2/3/2006 | 00300064047417 | 5/17/2022 | 00006-4047-02 | False | 2/1/2023 | 116 | rotavirus, pentavalent | MSD | ||
00006-4047-41 | RotaTeq | Merck Sharp & Dohme LLC | 2/3/2006 | 00300064047417 | 5/17/2022 | 00006-4047-01 | False | 00300064047011 | 2/1/2023 | 116 | rotavirus, pentavalent | MSD | |
00006-4093-02 | RECOMBIVAX HB | Merck Sharp & Dohme LLC | 7/23/1986 | 00300064093025 | 7/5/2022 | 00006-4093-01 | False | 00300064093018 | 2/1/2023 | 08 | Hep B, adolescent or pediatric | MSD | |
00006-4093-09 | RECOMBIVAX HB | Merck Sharp & Dohme LLC | 7/23/1986 | 6/13/2023 | 00300064093094 | 7/11/2023 | 00006-4093-01 | False | 00300064093018 | 2/1/2023 | 08 | Hep B, adolescent or pediatric | MSD |
00006-4094-02 | RECOMBIVAX HB | Merck Sharp & Dohme LLC | 7/23/1986 | 00300064094022 | 7/5/2022 | 00006-4094-01 | False | 00300064094015 | 2/1/2023 | 43 | Hep B, adult | MSD | |
00006-4094-09 | RECOMBIVAX HB | Merck Sharp & Dohme LLC | 7/23/1986 | 6/13/2023 | 00300064094091 | 7/11/2023 | 00006-4094-01 | False | 00300064094015 | 2/1/2023 | 43 | Hep B, adult | MSD |
00006-4095-02 | VAQTA | Merck Sharp & Dohme LLC | 3/29/1996 | 00300064095029 | 7/5/2022 | 00006-4095-01 | False | 00300064095012 | 2/1/2023 | 83 | Hep A, ped/adol, 2 dose | MSD | |
00006-4095-09 | VAQTA | Merck Sharp & Dohme Corp. | 3/29/1996 | 4/30/2019 | 00300064095098 | 5/21/2019 | 00006-4095-01 | False | 00300064095012 | 2/1/2023 | 83 | Hep A, ped/adol, 2 dose | MSD |
00006-4096-02 | VAQTA | Merck Sharp & Dohme LLC | 3/29/1996 | 00300064096026 | 7/5/2022 | 00006-4096-01 | False | 00300064096019 | 2/1/2023 | 52 | Hep A, adult | MSD | |
00006-4096-09 | VAQTA | Merck Sharp & Dohme Corp. | 3/29/1996 | 4/30/2019 | 00300064096095 | 5/21/2019 | 00006-4096-01 | False | 00300064096019 | 2/1/2023 | 52 | Hep A, adult | MSD |
00006-4109-02 | GARDASIL | Merck Sharp & Dohme LLC | 6/8/2006 | 7/5/2022 | 00006-4109-01 | False | 00300064109016 | 2/1/2023 | 62 | HPV, quadrivalent | MSD | ||
00006-4109-09 | GARDASIL | Merck Sharp & Dohme LLC | 6/8/2006 | 7/5/2022 | 00006-4109-01 | False | 00300064109016 | 2/1/2023 | 62 | HPV, quadrivalent | MSD | ||
00006-4119-02 | GARDASIL 9 | Merck Sharp & Dohme Corp. | 12/10/2014 | 4/30/2019 | 00300064119022 | 5/29/2019 | 00006-4119-01 | False | 00300064119015 | 2/1/2023 | 165 | HPV9 | MSD |
00006-4119-03 | GARDASIL 9 | Merck Sharp & Dohme LLC | 12/10/2014 | 00300064119039 | 6/22/2022 | 00006-4119-01 | False | 00300064119015 | 2/1/2023 | 165 | HPV9 | MSD | |
00006-4121-02 | GARDASIL 9 | Merck Sharp & Dohme LLC | 12/10/2014 | 00300064121025 | 6/22/2022 | 00006-4121-01 | False | 00300064121018 | 2/1/2023 | 165 | HPV9 | MSD | |
00006-4133-41 | Tetanus and Diphtheria Toxoids Adsorbed | Merck Sharp & Dohme Corp. | 7/27/1970 | 6/2/2014 | 7/22/2014 | 00006-4133-01 | False | 7/3/2018 | 09 | Td (adult), 2 Lf tetanus toxoid, preservative free, adsorbed | MSD | ||
00006-4171-00 | ProQuad | Merck Sharp & Dohme LLC | 8/1/2015 | 00300064171006 | 7/5/2022 | 00006-4171-01 | False | 00300064171013 | 2/1/2023 | 94 | MMRV | MSD | |
00006-4293-02 | ERVEBO | Merck Sharp & Dohme LLC | 12/19/2019 | 1/6/2023 | 00006-4293-01 | False | 2/1/2023 | 204 | Ebola Zaire vaccine, live, recombinant, 1mL dose | MSD | |||
00006-4329-02 | VAXNEUVANCE | Merck Sharp & Dohme LLC | 7/16/2021 | 00300064329025 | 10/17/2022 | 00006-4329-01 | False | 00300064329018 | 2/1/2023 | 215 | Pneumococcal conjugate PCV15, polysaccharide CRM197 conjugate, adjuvant, PF | MSD | |
00006-4329-03 | VAXNEUVANCE | Merck Sharp & Dohme LLC | 7/16/2021 | 00300064329032 | 10/17/2022 | 00006-4329-01 | False | 00300064329018 | 2/1/2023 | 215 | Pneumococcal conjugate PCV15, polysaccharide CRM197 conjugate, adjuvant, PF | MSD | |
00006-4347-01 | CAPVAXIVE | Merck Sharp & Dohme LLC | 6/17/2024 | 7/12/2024 | 00006-4347-99 | False | 7/11/2024 | 327 | Pneumococcal conjugate PCV21, polysaccharide CRM197 conjugate, PF | MSD | |||
00006-4347-02 | CAPVAXIVE | Merck Sharp & Dohme LLC | 6/17/2024 | 7/12/2024 | 00006-4347-99 | False | 7/11/2024 | 327 | Pneumococcal conjugate PCV21, polysaccharide CRM197 conjugate, PF | MSD | |||
00006-4681-00 | M-M-R II | Merck Sharp & Dohme LLC | 4/21/1971 | 00300064681000 | 6/22/2022 | 00006-4681-01 | False | 00300064681017 | 2/1/2023 | 03 | MMR | MSD | |
00006-4739-00 | PNEUMOVAX 23 | Merck Sharp & Dohme Corp. | 7/7/1983 | 4/30/2019 | 5/21/2019 | 00006-4739-01 | False | 00300064739015 | 5/21/2019 | 33 | pneumococcal polysaccharide PPV23 | MSD | |
00006-4826-00 | VARIVAX | Merck Sharp & Dohme LLC | 3/17/1995 | 6/13/2023 | 00300064826005 | 7/11/2023 | 00006-4826-01 | False | 00300064826012 | 10/26/2023 | 21 | varicella | MSD |
00006-4827-00 | VARIVAX | Merck Sharp & Dohme LLC | 3/17/1995 | 00300064827002 | 7/5/2022 | 00006-4827-01 | False | 00300064827019 | 2/1/2023 | 21 | varicella | MSD | |
00006-4831-41 | VAQTA | Merck Sharp & Dohme LLC | 3/29/1996 | 00300064831412 | 7/5/2022 | 00006-4831-01 | False | 00300064831016 | 2/1/2023 | 83 | Hep A, ped/adol, 2 dose | MSD | |
00006-4837-02 | PNEUMOVAX 23 | Merck Sharp & Dohme Corp. | 7/21/2014 | 1/1/2020 | 1/21/2020 | 00006-4837-01 | False | 00300064837018 | 2/1/2023 | 33 | pneumococcal polysaccharide PPV23 | MSD | |
00006-4837-03 | PNEUMOVAX 23 | Merck Sharp & Dohme LLC | 5/30/2014 | 00300064837032 | 5/30/2023 | 00006-4837-01 | False | 00300064837018 | 2/1/2023 | 33 | pneumococcal polysaccharide PPV23 | MSD | |
00006-4841-00 | VAQTA | Merck Sharp & Dohme LLC | 3/29/1996 | 00300064841008 | 7/5/2022 | 00006-4841-01 | False | 00300064841015 | 2/1/2023 | 52 | Hep A, adult | MSD | |
00006-4841-41 | VAQTA | Merck Sharp & Dohme LLC | 3/29/1996 | 00300064841411 | 7/5/2022 | 00006-4841-01 | False | 00300064841015 | 2/1/2023 | 52 | Hep A, adult | MSD | |
00006-4897-00 | PedvaxHIB | Merck Sharp & Dohme LLC | 12/20/1989 | 00300064897005 | 6/22/2022 | 00006-4897-01 | False | 00300064897012 | 2/1/2023 | 49 | Hib (PRP-OMP) | MSD | |
00006-4898-00 | COMVAX | Merck Sharp & Dohme Corp. | 10/2/1996 | 12/31/2014 | 5/30/2018 | 00006-4898-01 | False | 00300064898019 | 5/30/2018 | 51 | Hib-Hep B | MSD | |
00006-4943-00 | PNEUMOVAX 23 | Merck Sharp & Dohme LLC | 7/7/1983 | 00300064943009 | 6/13/2022 | 00006-4943-01 | False | 00300064943016 | 2/1/2023 | 33 | pneumococcal polysaccharide PPV23 | MSD | |
00006-4963-00 | ZOSTAVAX | Merck Sharp & Dohme LLC | 5/25/2006 | 9/19/2022 | 00300064963007 | 10/17/2022 | 00006-4963-01 | False | 00300064963014 | 10/17/2022 | 121 | zoster live | MSD |
00006-4963-41 | ZOSTAVAX | Merck Sharp & Dohme LLC | 5/25/2006 | 9/19/2022 | 00300064963410 | 10/17/2022 | 00006-4963-01 | False | 00300064963014 | 10/17/2022 | 121 | zoster live | MSD |
00006-4980-00 | RECOMBIVAX HB | Merck Sharp & Dohme Corp. | 7/23/1986 | 9/19/2008 | 7/13/2018 | 00006-4980-00 | True | 11/20/2017 | 08 | Hep B, adolescent or pediatric | MSD | ||
00006-4981-00 | RECOMBIVAX HB | Merck Sharp & Dohme LLC | 7/23/1986 | 00300064981001 | 7/5/2022 | 00006-4981-01 | False | 00300064981018 | 2/1/2023 | 08 | Hep B, adolescent or pediatric | MSD | |
00006-4992-00 | RECOMBIVAX HB | Merck Sharp & Dohme LLC | 7/23/1986 | 00300064992007 | 7/5/2022 | 00006-4992-01 | False | 00300064992014 | 2/1/2023 | 44 | Hep B, dialysis | MSD | |
00006-4995-00 | RECOMBIVAX HB | Merck Sharp & Dohme LLC | 7/23/1986 | 00300064995008 | 7/5/2022 | 00006-4995-01 | False | 00300064995015 | 2/1/2023 | 43 | Hep B, adult | MSD | |
00006-4995-41 | RECOMBIVAX HB | Merck Sharp & Dohme LLC | 7/23/1986 | 00300064995411 | 7/5/2022 | 00006-4995-01 | False | 00300064995015 | 2/1/2023 | 43 | Hep B, adult | MSD | |
00006-4999-00 | ProQuad | Merck Sharp & Dohme Corp. | 9/6/2005 | 7/31/2015 | 00300064999006 | 9/13/2018 | 00006-4999-01 | False | 00300064999013 | 9/13/2018 | 94 | MMRV | MSD |
00052-0603-02 | BCG VACCINE | Merck Sharp & Dohme LLC | 6/21/1989 | 6/22/2022 | 00052-0603-01 | False | 2/1/2023 | 19 | BCG | MSD | |||
00069-0297-02 | TicoVac | Pfizer Laboratories Div Pfizer Inc | 6/27/2022 | 00300690297026 | 10/17/2022 | 00069-0297-01 | False | 10300690297016 | 2/1/2023 | 223 | Tick-borne encephalitis, inactivated, PF, 0.25mL | PFR | |
00069-0297-10 | TicoVac | Pfizer Laboratories Div Pfizer Inc | 6/27/2022 | 00300690297101 | 10/17/2022 | 00069-0297-01 | False | 10300690297016 | 2/1/2023 | 223 | Tick-borne encephalitis, inactivated, PF, 0.25mL | PFR | |
00069-0344-01 | Abrysvo | Pfizer Laboratories Div Pfizer Inc | 7/12/2023 | 00300690344010 | 9/17/2024 | 00069-0207-01 | False | 10300690207015 | 9/17/2024 | 305 | RSV, bivalent, protein subunit RSVpreF, diluent reconstituted, 0.5 mL, PF | PFR | |
00069-0344-05 | Abrysvo | Pfizer Laboratories Div Pfizer Inc | 7/12/2023 | 00300690344058 | 9/17/2024 | 00069-0207-01 | False | 10300690207015 | 9/17/2024 | 305 | RSV, bivalent, protein subunit RSVpreF, diluent reconstituted, 0.5 mL, PF | PFR | |
00069-0344-10 | Abrysvo | Pfizer Laboratories Div Pfizer Inc | 7/12/2023 | 00300690344102 | 9/17/2024 | 00069-0207-01 | False | 10300690207015 | 9/17/2024 | 305 | RSV, bivalent, protein subunit RSVpreF, diluent reconstituted, 0.5 mL, PF | PFR | |
00069-0411-02 | TicoVac | Pfizer Laboratories Div Pfizer Inc | 10/25/2021 | 00300690411026 | 10/18/2022 | 00069-0411-01 | False | 10300690411016 | 2/1/2023 | 224 | Tick-borne encephalitis, inactivated, PF, 0.5mL | PFR | |
00069-0411-10 | TicoVac | Pfizer Laboratories Div Pfizer Inc | 10/25/2021 | 00300690411101 | 10/18/2022 | 00069-0411-01 | False | 10300690411016 | 2/1/2023 | 224 | Tick-borne encephalitis, inactivated, PF, 0.5mL | PFR | |
00069-0600-01 | PENBRAYA | Pfizer Laboratories Div Pfizer Inc | 11/27/2023 | 00300690600017 | 9/17/2024 | 00069-0332-01 | False | 10300690332014 | 9/17/2024 | 316 | Meningococcal polysaccharide (MenACWY-TT conjugate), (MenB), PF | PFR | |
00069-0600-01 | PENBRAYA | Pfizer Laboratories Div Pfizer Inc | 11/27/2023 | 00300690600017 | 9/17/2024 | 00069-0271-01 | False | 10300690271016 | 9/17/2024 | 316 | Meningococcal polysaccharide (MenACWY-TT conjugate), (MenB), PF | PFR | |
00069-0600-05 | PENBRAYA | Pfizer Laboratories Div Pfizer Inc | 11/27/2023 | 00300690600055 | 9/17/2024 | 00069-0271-01 | False | 10300690271016 | 9/17/2024 | 316 | Meningococcal polysaccharide (MenACWY-TT conjugate), (MenB), PF | PFR | |
00069-0600-05 | PENBRAYA | Pfizer Laboratories Div Pfizer Inc | 11/27/2023 | 00300690600055 | 9/17/2024 | 00069-0332-01 | False | 10300690332014 | 9/17/2024 | 316 | Meningococcal polysaccharide (MenACWY-TT conjugate), (MenB), PF | PFR | |
00069-0600-10 | PENBRAYA | Pfizer Laboratories Div Pfizer Inc | 11/27/2023 | 00300690600109 | 9/17/2024 | 00069-0332-01 | False | 10300690332014 | 9/17/2024 | 316 | Meningococcal polysaccharide (MenACWY-TT conjugate), (MenB), PF | PFR | |
00069-0600-10 | PENBRAYA | Pfizer Laboratories Div Pfizer Inc | 11/27/2023 | 00300690600109 | 9/17/2024 | 00069-0271-01 | False | 10300690271016 | 9/17/2024 | 316 | Meningococcal polysaccharide (MenACWY-TT conjugate), (MenB), PF | PFR | |
00069-2025-10 | Comirnaty | Pfizer Laboratories Div Pfizer Inc | 5/18/2022 | 9/11/2023 | 00300692025108 | 2/6/2024 | 00069-2025-01 | False | 10300692025013 | 2/6/2024 | 217 | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose | PFR |
00069-2025-25 | Comirnaty | Pfizer Laboratories Div Pfizer Inc | 3/1/2022 | 9/11/2023 | 00300692025252 | 2/6/2024 | 00069-2025-01 | False | 10300692025013 | 2/6/2024 | 217 | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose | PFR |
00069-2362-10 | Comirnaty | Pfizer Laboratories Div Pfizer Inc | 9/11/2023 | 8/21/2024 | 00300692362104 | 9/19/2024 | 00069-2362-01 | False | 10300692362019 | 9/19/2024 | 309 | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 30 mcg/0.3 mL | PFR |
00069-2377-10 | Comirnaty | Pfizer Laboratories Div Pfizer Inc | 10/31/2023 | 8/21/2024 | 00300692377108 | 9/19/2024 | 00069-2377-01 | False | 10300692377013 | 9/19/2024 | 309 | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 30 mcg/0.3 mL | PFR |
00069-2392-10 | Comirnaty | Pfizer Laboratories Div Pfizer Inc | 9/11/2023 | 6/30/2024 | 7/18/2024 | 00069-2392-01 | False | 7/18/2024 | 309 | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 30 mcg/0.3 mL | PFR | ||
00069-2432-10 | Comirnaty | Pfizer Laboratories Div Pfizer Inc | 8/22/2024 | 00300692432104 | 10/9/2024 | 00069-2432-01 | False | 10300692432019 | 10/9/2024 | 309 | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 30 mcg/0.3 mL | PFR | |
00069-2465-01 | Abrysvo | Pfizer Laboratories Div Pfizer Inc | 7/30/2024 | 8/6/2024 | 00069-2465-19 | False | 8/6/2024 | 305 | RSV, bivalent, protein subunit RSVpreF, diluent reconstituted, 0.5 mL, PF | PFR | |||
00069-2465-10 | Abrysvo | Pfizer Laboratories Div Pfizer Inc | 7/30/2024 | 8/6/2024 | 00069-2465-19 | False | 8/6/2024 | 305 | RSV, bivalent, protein subunit RSVpreF, diluent reconstituted, 0.5 mL, PF | PFR | |||
13533-0131-01 | TDVAX | Grifols USA, LLC | 7/1/2015 | 20313533131016 | 3/12/2024 | 13533-0131-00 | False | 00313533131005 | 3/12/2024 | 09 | Td (adult), 2 Lf tetanus toxoid, preservative free, adsorbed | MBL | |
14362-0111-04 | TDVAX | MassBiologics | 7/27/1970 | 20314362011142 | 3/12/2024 | 14362-0111-03 | False | 00314362011131 | 3/12/2024 | 09 | Td (adult), 2 Lf tetanus toxoid, preservative free, adsorbed | MBL | |
17478-0131-01 | Tetanus and Diphtheria Toxoids Adsorbed | Akorn, Inc. | 2/15/2013 | 4/27/2017 | 7/6/2018 | 17478-0131-00 | False | 5/30/2018 | 09 | Td (adult), 2 Lf tetanus toxoid, preservative free, adsorbed | MBL | ||
19515-0808-52 | Flulaval Quadrivalent | ID Biomedical Corporation of Quebec | 7/1/2022 | 6/30/2023 | 00319515808521 | 7/18/2024 | 19515-0808-41 | False | 10319515808412 | 7/18/2024 | 150 | Influenza, split virus, quadrivalent, PF | IDB |
19515-0810-52 | FLULAVAL | ID Biomedical Corporation of Quebec | 7/1/2024 | 7/18/2024 | 19515-0810-41 | False | 7/23/2024 | 140 | Influenza, split virus, trivalent, PF | IDB | |||
19515-0814-52 | Flulaval Quadrivalent | ID Biomedical Corporation of Quebec | 7/1/2023 | 6/30/2024 | 7/18/2024 | 19515-0814-41 | False | 7/23/2024 | 150 | Influenza, split virus, quadrivalent, PF | IDB | ||
19515-0816-52 | Flulaval Quadrivalent | ID Biomedical Corporation of Quebec | 7/2/2020 | 6/30/2021 | 7/18/2024 | 19515-0816-41 | False | 7/18/2024 | 150 | Influenza, split virus, quadrivalent, PF | IDB | ||
19515-0818-52 | Flulaval Quadrivalent | ID Biomedical Corporation of Quebec | 7/2/2021 | 6/30/2022 | 00319515818520 | 7/18/2024 | 19515-0818-41 | False | 10319515818411 | 7/18/2024 | 150 | Influenza, split virus, quadrivalent, PF | IDB |
19515-0845-11 | FLULAVAL | ID Biomedical | 10/30/2015 | 10/31/2015 | 7/12/2018 | 19515-0845-01 | False | 7/3/2018 | 141 | Influenza, split virus, trivalent, preservative | IDB | ||
19515-0850-52 | FLULAVAL | ID Biomedical | 7/1/2015 | 10/31/2015 | 7/12/2018 | 19515-0850-41 | False | 7/3/2018 | 140 | Influenza, split virus, trivalent, PF | IDB | ||
19515-0889-07 | FLULAVAL | ID Biomedical Corporation of Quebec | 7/20/2012 | 7/1/2013 | 12/7/2017 | 19515-0889-02 | False | 11/20/2017 | 141 | Influenza, split virus, trivalent, preservative | IDB | ||
19515-0890-07 | FLULAVAL | ID Biomedical Corporation of Quebec | 7/1/2013 | 6/30/2014 | 12/7/2017 | 19515-0890-02 | False | 11/20/2017 | 141 | Influenza, split virus, trivalent, preservative | IDB | ||
19515-0891-11 | Flulaval Quadrivalent | ID Biomedical Corporation of Quebec | 7/1/2014 | 6/30/2015 | 5/30/2018 | 19515-0891-01 | False | 5/30/2018 | 158 | Influenza, split virus, quadrivalent, preservative | IDB | ||
19515-0893-07 | FLULAVAL | ID Biomedical Corporation of Quebec | 7/1/2014 | 6/30/2015 | 5/30/2018 | 19515-0893-02 | False | 00319515893022 | 5/30/2018 | 141 | Influenza, split virus, trivalent, preservative | IDB | |
19515-0894-52 | Flulaval Quadrivalent | ID Biomedical Corporation of Quebec | 7/1/2014 | 6/30/2015 | 5/30/2018 | 19515-0894-41 | False | 5/30/2018 | 150 | Influenza, split virus, quadrivalent, PF | IDB | ||
19515-0895-11 | Flulaval Quadrivalent | ID Biomedical Corporation of Quebec | 8/15/2013 | 6/30/2014 | 12/7/2017 | 19515-0895-01 | False | 11/20/2017 | 158 | Influenza, split virus, quadrivalent, preservative | IDB | ||
19515-0896-11 | Flulaval Quadrivalent | ID Biomedical Corporation of Quebec | 7/7/2017 | 6/30/2018 | 00319515896115 | 7/9/2018 | 19515-0896-01 | False | 00319515896016 | 7/9/2018 | 158 | Influenza, split virus, quadrivalent, preservative | IDB |
19515-0897-11 | Flulaval Quadrivalent | ID Biomedical Corporation of Quebec | 7/2/2019 | 6/30/2020 | 7/18/2024 | 19515-0897-01 | False | 7/18/2024 | 158 | Influenza, split virus, quadrivalent, preservative | IDB | ||
19515-0898-11 | Flulaval Quadrivalent | ID Biomedical Corporation of Quebec | 7/1/2015 | 6/30/2016 | 5/30/2018 | 19515-0898-01 | False | 00319515898010 | 5/30/2018 | 158 | Influenza, split virus, quadrivalent, preservative | IDB | |
19515-0900-11 | Flulaval Quadrivalent | ID Biomedical Corporation of Quebec | 6/29/2018 | 6/30/2019 | 00319515900119 | 7/16/2019 | 19515-0900-01 | False | 00319515900010 | 7/16/2019 | 158 | Influenza, split virus, quadrivalent, preservative | IDB |
19515-0901-52 | Flulaval Quadrivalent | ID Biomedical Corporation of Quebec | 7/1/2015 | 6/30/2016 | 5/30/2018 | 19515-0901-41 | False | 00319515901413 | 5/30/2018 | 150 | Influenza, split virus, quadrivalent, PF | IDB | |
19515-0903-11 | Flulaval Quadrivalent | ID Biomedical Corporation of Quebec | 7/1/2016 | 6/30/2017 | 7/11/2018 | 19515-0903-01 | False | 7/3/2018 | 158 | Influenza, split virus, quadrivalent, preservative | IDB | ||
19515-0906-52 | Flulaval Quadrivalent | ID Biomedical Corporation of Quebec | 7/2/2019 | 6/30/2020 | 7/18/2024 | 19515-0906-41 | False | 7/18/2024 | 150 | Influenza, split virus, quadrivalent, PF | IDB | ||
19515-0908-52 | Flulaval Quadrivalent | ID Biomedical Corporation of Quebec | 7/1/2016 | 6/30/2017 | 7/11/2018 | 19515-0908-41 | False | 7/3/2018 | 150 | Influenza, split virus, quadrivalent, PF | IDB | ||
19515-0909-52 | Flulaval Quadrivalent | ID Biomedical Corporation of Quebec | 6/29/2018 | 6/30/2019 | 00319515909525 | 7/16/2019 | 19515-0909-41 | False | 00319515909419 | 7/16/2019 | 150 | Influenza, split virus, quadrivalent, PF | IDB |
19515-0912-52 | Flulaval Quadrivalent | ID Biomedical Corporation of Quebec | 7/7/2017 | 6/30/2018 | 00319515912525 | 7/9/2018 | 19515-0912-41 | False | 00319515912419 | 7/9/2018 | 150 | Influenza, split virus, quadrivalent, PF | IDB |
21695-0413-01 | Tetanus and Diphtheria Toxoids Adsorbed | Rebel Distributors | 10/13/1967 | 10/4/2019 | 10/15/2019 | 21695-0413-01 | True | 10/11/2019 | 09 | Td (adult), 2 Lf tetanus toxoid, preservative free, adsorbed | MBL | ||
33332-0010-01 | AFLURIA | CSL Limited | 7/30/2010 | 6/30/2011 | 1/29/2018 | 33332-0010-01 | True | 2/27/2018 | 140 | Influenza, split virus, trivalent, PF | CSL | ||
33332-0013-01 | AFLURIA | CSL Limited | 7/1/2013 | 6/30/2014 | 7/13/2018 | 33332-0013-02 | False | 11/20/2017 | 140 | Influenza, split virus, trivalent, PF | CSL | ||
33332-0014-01 | AFLURIA | CSL Limited | 7/15/2014 | 6/30/2015 | 12/7/2017 | 33332-0014-02 | False | 7/3/2018 | 140 | Influenza, split virus, trivalent, PF | CSL | ||
33332-0015-01 | AFLURIA | bioCSL Pty Ltd. | 7/1/2015 | 6/30/2016 | 10/8/2019 | 33332-0015-02 | False | 10/8/2019 | 140 | Influenza, split virus, trivalent, PF | CSL | ||
33332-0016-01 | AFLURIA | Seqirus Pty Ltd | 7/1/2016 | 6/30/2017 | 7/11/2018 | 33332-0016-02 | False | 7/3/2018 | 140 | Influenza, split virus, trivalent, PF | SEQ | ||
33332-0017-01 | AFLURIA | Seqirus Pty Ltd | 7/1/2017 | 6/30/2018 | 8/13/2018 | 33332-0017-02 | False | 8/13/2018 | 140 | Influenza, split virus, trivalent, PF | SEQ | ||
33332-0018-01 | AFLURIA | Seqirus Pty Ltd | 7/1/2018 | 12/20/2019 | 1/21/2020 | 33332-0018-02 | False | 1/21/2020 | 140 | Influenza, split virus, trivalent, PF | SEQ | ||
33332-0024-03 | Afluria | Seqirus PTY LTD. | 7/1/2024 | 00333332024032 | 9/27/2024 | 33332-0024-04 | False | 00333332024049 | 9/27/2024 | 140 | Influenza, split virus, trivalent, PF | SEQ | |
33332-0110-10 | AFLURIA | CSL Limited | 7/30/2010 | 6/30/2011 | 1/29/2018 | 33332-0110-10 | True | 1/29/2018 | 141 | Influenza, split virus, trivalent, preservative | CSL | ||
33332-0113-10 | AFLURIA | CSL Limited | 7/1/2013 | 6/30/2014 | 7/13/2018 | 33332-0113-11 | False | 7/3/2018 | 141 | Influenza, split virus, trivalent, preservative | CSL | ||
33332-0114-10 | AFLURIA | CSL Limited | 7/15/2014 | 6/30/2015 | 7/13/2018 | 33332-0114-11 | False | 7/3/2018 | 141 | Influenza, split virus, trivalent, preservative | CSL | ||
33332-0115-10 | AFLURIA | bioCSL Pty Ltd. | 7/1/2015 | 6/30/2016 | 10/8/2019 | 33332-0115-11 | False | 10/8/2019 | 141 | Influenza, split virus, trivalent, preservative | CSL | ||
33332-0116-10 | AFLURIA | Seqirus Pty Ltd | 7/1/2016 | 6/30/2017 | 7/11/2018 | 33332-0116-11 | False | 7/3/2018 | 141 | Influenza, split virus, trivalent, preservative | SEQ | ||
33332-0117-10 | AFLURIA | Seqirus Pty Ltd | 7/1/2017 | 6/30/2018 | 8/13/2018 | 33332-0117-11 | False | 8/13/2018 | 141 | Influenza, split virus, trivalent, preservative | SEQ | ||
33332-0118-10 | AFLURIA | Seqirus Pty Ltd | 7/1/2018 | 12/20/2019 | 1/21/2020 | 33332-0118-11 | False | 1/21/2020 | 141 | Influenza, split virus, trivalent, preservative | SEQ | ||
33332-0124-10 | Afluria | Seqirus PTY LTD. | 7/1/2024 | 00333332124107 | 9/27/2024 | 33332-0124-11 | False | 00333332124114 | 9/27/2024 | 141 | Influenza, split virus, trivalent, preservative | SEQ | |
33332-0219-20 | Afluria Quadrivalent | Seqirus Pty Ltd. | 7/2/2019 | 7/31/2020 | 00333332219209 | 7/18/2024 | 33332-0219-21 | False | 00333332219216 | 7/18/2024 | 161 | Influenza, injectable,quadrivalent, preservative free, pediatric | SEQ |
33332-0220-20 | Afluria Quadrivalent | Seqirus Pty Ltd. | 7/2/2020 | 7/1/2021 | 7/18/2024 | 33332-0220-21 | False | 7/18/2024 | 161 | Influenza, injectable,quadrivalent, preservative free, pediatric | SEQ | ||
33332-0221-20 | Afluria Quadrivalent | Seqirus PTY LTD. | 7/2/2021 | 6/30/2022 | 7/18/2024 | 33332-0221-21 | False | 7/18/2024 | 161 | Influenza, injectable,quadrivalent, preservative free, pediatric | SEQ | ||
33332-0316-01 | AFLURIA QUADRIVALENT | Seqirus | 7/1/2016 | 6/30/2017 | 7/13/2018 | 33332-0316-02 | False | 7/3/2018 | 150 | Influenza, split virus, quadrivalent, PF | SEQ | ||
33332-0317-01 | AFLURIA QUADRIVALENT | Seqirus Pty Ltd | 7/1/2017 | 6/30/2018 | 8/13/2018 | 33332-0317-02 | False | 8/13/2018 | 150 | Influenza, split virus, quadrivalent, PF | SEQ | ||
33332-0318-01 | AFLURIA QUADRIVALENT | Seqirus Pty Ltd | 7/1/2018 | 6/30/2019 | 12/20/2019 | 33332-0318-02 | False | 12/20/2019 | 150 | Influenza, split virus, quadrivalent, PF | SEQ | ||
33332-0319-01 | Afluria Quadrivalent | Seqirus Pty Ltd. | 7/1/2019 | 7/31/2020 | 00333332319015 | 7/18/2024 | 33332-0319-02 | False | 00333332319022 | 7/18/2024 | 150 | Influenza, split virus, quadrivalent, PF | SEQ |
33332-0320-01 | Afluria Quadrivalent | Seqirus Pty Ltd. | 7/2/2020 | 7/1/2021 | 7/18/2024 | 33332-0320-02 | False | 7/18/2024 | 150 | Influenza, split virus, quadrivalent, PF | SEQ | ||
33332-0321-01 | Afluria Quadrivalent | Seqirus PTY LTD. | 7/2/2021 | 6/30/2022 | 7/18/2024 | 33332-0321-02 | False | 7/18/2024 | 150 | Influenza, split virus, quadrivalent, PF | SEQ | ||
33332-0322-03 | Afluria Quadrivalent | Seqirus PTY LTD. | 7/1/2022 | 6/30/2023 | 00333332322039 | 7/18/2024 | 33332-0322-04 | False | 00333332322046 | 7/18/2024 | 150 | Influenza, split virus, quadrivalent, PF | SEQ |
33332-0323-03 | Afluria Quadrivalent | Seqirus PTY LTD. | 7/1/2023 | 6/30/2024 | 00333332323036 | 8/6/2024 | 33332-0323-04 | False | 00333332323043 | 8/6/2024 | 150 | Influenza, split virus, quadrivalent, PF | SEQ |
33332-0416-10 | AFLURIA QUADRIVALENT | Seqirus | 7/1/2016 | 6/30/2017 | 7/13/2018 | 33332-0416-11 | False | 7/3/2018 | 158 | Influenza, split virus, quadrivalent, preservative | SEQ | ||
33332-0417-10 | AFLURIA QUADRIVALENT | Seqirus Pty Ltd | 8/16/2017 | 6/30/2018 | 8/13/2018 | 33332-0417-11 | False | 8/13/2018 | 158 | Influenza, split virus, quadrivalent, preservative | SEQ | ||
33332-0418-10 | AFLURIA QUADRIVALENT | Seqirus Pty Ltd | 7/1/2018 | 6/30/2019 | 12/20/2019 | 33332-0418-11 | False | 12/20/2019 | 158 | Influenza, split virus, quadrivalent, preservative | SEQ | ||
33332-0419-10 | Afluria Quadrivalent | Seqirus Pty Ltd. | 7/1/2019 | 7/31/2020 | 00333332419104 | 7/18/2024 | 33332-0419-11 | False | 00333332419111 | 7/18/2024 | 158 | Influenza, split virus, quadrivalent, preservative | SEQ |
33332-0420-10 | Afluria Quadrivalent | Seqirus Pty Ltd. | 7/2/2020 | 7/1/2021 | 7/18/2024 | 33332-0420-11 | False | 7/18/2024 | 158 | Influenza, split virus, quadrivalent, preservative | SEQ | ||
33332-0421-10 | Afluria Quadrivalent | Seqirus PTY LTD. | 7/2/2021 | 6/30/2022 | 7/18/2024 | 33332-0421-11 | False | 7/18/2024 | 158 | Influenza, split virus, quadrivalent, preservative | SEQ | ||
33332-0422-10 | Afluria Quadrivalent | Seqirus PTY LTD. | 7/1/2022 | 6/30/2023 | 7/18/2024 | 33332-0422-11 | False | 00333332422111 | 7/18/2024 | 158 | Influenza, split virus, quadrivalent, preservative | SEQ | |
33332-0423-10 | Afluria Quadrivalent | Seqirus PTY LTD. | 7/1/2023 | 6/30/2024 | 00333332423101 | 8/6/2024 | 33332-0423-11 | False | 00333332423118 | 8/6/2024 | 158 | Influenza, split virus, quadrivalent, preservative | SEQ |
33332-0519-01 | Influenza A | CSL Limited | 7/1/2009 | 6/30/2010 | 1/29/2018 | 33332-0519-01 | True | 1/29/2018 | 126 | Novel influenza-H1N1-09, preservative-free | CSL | ||
33332-0519-25 | Influenza A | CSL Limited | 7/1/2009 | 6/30/2010 | 1/29/2018 | 33332-0519-25 | True | 1/29/2018 | 126 | Novel influenza-H1N1-09, preservative-free | CSL | ||
33332-0629-10 | Influenza A | CSL Limited | 7/1/2009 | 6/30/2010 | 1/29/2018 | 33332-0629-10 | True | 1/29/2018 | 127 | Novel influenza-H1N1-09 | CSL | ||
42515-0001-01 | IXIARO | Valneva Scotland Ltd. | 3/30/2009 | 2/13/2018 | 3/7/2023 | 42515-0001-00 | False | 3/7/2023 | 134 | Japanese Encephalitis IM | VAL | ||
42515-0001-01 | IXIARO | Valneva Scotland Ltd. | 3/30/2009 | 2/13/2018 | 3/7/2023 | 42515-0001-00 | False | 3/7/2023 | 134 | Japanese Encephalitis IM | INT | ||
42515-0001-01 | IXIARO | Valneva Scotland Ltd. | 3/30/2009 | 2/13/2018 | 3/7/2023 | 42515-0001-01 | True | 10/15/2019 | 134 | Japanese Encephalitis IM | VAL | ||
42515-0001-01 | IXIARO | Valneva Scotland Ltd. | 3/30/2009 | 2/13/2018 | 3/7/2023 | 42515-0001-01 | True | 10/15/2019 | 134 | Japanese Encephalitis IM | INT | ||
42515-0002-01 | IXIARO | Valneva Scotland Ltd. | 3/30/2009 | 7/12/2018 | 42515-0002-01 | True | 4/6/2018 | 134 | Japanese Encephalitis IM | VAL | |||
42515-0003-01 | IXCHIQ | Valneva Scotland Ltd. | 1/15/2024 | 00342515003016 | 9/27/2024 | 42515-0003-00 | False | 10/9/2024 | 317 | Chikungunya live attenuated vaccine, 0.5 mL, PF | VAL | ||
42874-0012-10 | Flublok | Protein Sciences Corporation | 2/1/2013 | 6/30/2013 | 10/8/2019 | 42874-0012-01 | False | 10/8/2019 | 155 | Influenza, recombinant, trivalent, PF | PSC | ||
42874-0013-10 | Flublok | Protein Sciences Corporation | 11/1/2013 | 6/30/2014 | 10/8/2019 | 42874-0013-01 | False | 10/8/2019 | 155 | Influenza, recombinant, trivalent, PF | PSC | ||
42874-0014-10 | Flublok | Protein Sciences Corporation | 9/15/2014 | 6/30/2015 | 10/8/2019 | 42874-0014-01 | False | 10/8/2019 | 155 | Influenza, recombinant, trivalent, PF | PSC | ||
42874-0015-10 | Flublok | Protein Sciences Corporation | 8/7/2015 | 6/30/2016 | 10/8/2019 | 42874-0015-01 | False | 10/8/2019 | 155 | Influenza, recombinant, trivalent, PF | PSC | ||
42874-0016-10 | Flublok | Protein Sciences Corporation | 8/1/2016 | 6/30/2017 | 10/8/2019 | 42874-0016-01 | False | 10/8/2019 | 155 | Influenza, recombinant, trivalent, PF | PSC | ||
42874-0017-10 | Flublok | Protein Sciences Corporation | 7/14/2017 | 6/30/2018 | 10/8/2019 | 42874-0017-01 | False | 10/8/2019 | 155 | Influenza, recombinant, trivalent, PF | PSC | ||
42874-0117-10 | Flublok Quadrivalent | Protein Sciences Corporation | 7/14/2017 | 6/30/2018 | 7/9/2018 | 42874-0117-01 | False | 7/9/2018 | 185 | Influenza, recombinant, quadrivalent, PF | PSC | ||
43528-0002-05 | HEPLISAV-B | Dynavax Technologies Corporation | 1/1/2018 | 12/20/2019 | 00343528002058 | 1/21/2020 | 43528-0002-01 | False | 00343528002010 | 1/21/2020 | 189 | HepB-CpG | DVX |
43528-0003-05 | HEPLISAV-B | Dynavax Technologies Corporation | 1/1/2018 | 00343528003055 | 2/2/2023 | 43528-0003-01 | False | 00343528003017 | 2/2/2023 | 189 | HepB-CpG | DVX | |
46028-0114-01 | Bexsero | Novartis Vaccines and Diagnostics SRL | 1/23/2015 | 10/31/2017 | 5/30/2018 | 46028-0114-11 | False | 5/30/2018 | 163 | meningococcal B, OMV | NOV | ||
46028-0114-02 | Bexsero | Novartis Vaccines and Diagnostics SRL | 1/23/2015 | 10/31/2017 | 5/30/2018 | 46028-0114-11 | False | 5/30/2018 | 163 | meningococcal B, OMV | NOV | ||
46028-0208-01 | Menveo | Novartis Vaccines and Diagnostics s.r.l. | 2/19/2010 | 4/30/2018 | 12/16/2022 | 46028-0219-11 | False | 00346028219117 | 5/16/2018 | 136 | Meningococcal MCV4O | NOV | |
46028-0208-01 | Menveo | Novartis Vaccines and Diagnostics s.r.l. | 2/19/2010 | 4/30/2018 | 12/16/2022 | 46028-0218-11 | False | 00346028218110 | 5/16/2018 | 136 | Meningococcal MCV4O | NOV | |
49281-0010-10 | FLUZONE | Sanofi Pasteur Inc. | 7/23/2010 | 6/30/2011 | 1/29/2018 | 49281-0010-10 | True | 00349281010101 | 7/4/2018 | 140 | Influenza, split virus, trivalent, PF | PMC | |
49281-0010-25 | FLUZONE | Sanofi Pasteur Inc. | 7/23/2010 | 6/30/2011 | 1/29/2018 | 49281-0010-25 | True | 00349281010255 | 9/19/2018 | 140 | Influenza, split virus, trivalent, PF | PMC | |
49281-0010-50 | FLUZONE | Sanofi Pasteur Inc. | 7/23/2010 | 6/30/2011 | 1/29/2018 | 49281-0010-50 | True | 00349281010507 | 7/4/2018 | 140 | Influenza, split virus, trivalent, PF | PMC | |
49281-0011-10 | FLUZONE | Sanofi Pasteur Inc. | 7/1/2011 | 6/30/2012 | 1/29/2018 | 49281-0011-10 | True | 00349281011108 | 2/13/2018 | 140 | Influenza, split virus, trivalent, PF | PMC | |
49281-0011-50 | FLUZONE | Sanofi Pasteur Inc. | 7/1/2011 | 6/30/2012 | 1/29/2018 | 49281-0011-50 | True | 00349281011504 | 1/29/2018 | 140 | Influenza, split virus, trivalent, PF | PMC | |
49281-0012-10 | FLUZONE | Sanofi Pasteur Inc. | 7/2/2012 | 6/30/2013 | 12/7/2017 | 49281-0012-10 | True | 00349281012105 | 7/4/2018 | 140 | Influenza, split virus, trivalent, PF | PMC | |
49281-0012-50 | FLUZONE | Sanofi Pasteur Inc. | 7/2/2012 | 6/30/2013 | 12/7/2017 | 49281-0012-50 | True | 00349281012501 | 11/20/2017 | 140 | Influenza, split virus, trivalent, PF | PMC | |
49281-0013-10 | FLUZONE | Sanofi Pasteur Inc. | 6/28/2013 | 6/30/2014 | 12/7/2017 | 49281-0013-58 | False | 00349281013584 | 11/20/2017 | 140 | Influenza, split virus, trivalent, PF | PMC | |
49281-0013-50 | FLUZONE | Sanofi Pasteur Inc. | 6/28/2013 | 6/30/2014 | 12/7/2017 | 49281-0013-88 | False | 00349281013881 | 11/20/2017 | 140 | Influenza, split virus, trivalent, PF | PMC | |
49281-0014-50 | FLUZONE | Sanofi Pasteur Inc. | 6/27/2014 | 6/30/2015 | 7/6/2018 | 49281-0014-88 | False | 00349281014888 | 7/4/2018 | 140 | Influenza, split virus, trivalent, PF | PMC | |
49281-0111-25 | FLUZONE | Sanofi Pasteur Inc. | 7/1/2011 | 6/30/2012 | 1/29/2018 | 49281-0111-25 | True | 00349281111259 | 7/4/2018 | 140 | Influenza, split virus, trivalent, PF | PMC | |
49281-0112-25 | FLUZONE | Sanofi Pasteur Inc. | 7/2/2012 | 6/30/2013 | 12/7/2017 | 49281-0112-25 | True | 00349281112256 | 7/4/2018 | 140 | Influenza, split virus, trivalent, PF | PMC | |
49281-0113-25 | FLUZONE | Sanofi Pasteur Inc. | 6/28/2013 | 6/30/2014 | 12/7/2017 | 49281-0113-00 | False | 00349281113000 | 11/20/2017 | 140 | Influenza, split virus, trivalent, PF | PMC | |
49281-0120-65 | FLUZONE High-Dose Quadrivalent Northern Hemisphere | Sanofi Pasteur Inc. | 11/1/2019 | 6/30/2021 | 7/18/2024 | 49281-0120-88 | False | 7/18/2024 | 197 | Influenza, high-dose, quadrivalent, PF | PMC | ||
49281-0121-65 | FLUZONE High-Dose Quadrivalent Northern Hemisphere | Sanofi Pasteur Inc. | 7/2/2021 | 6/30/2022 | 00349281121654 | 7/18/2024 | 49281-0121-88 | False | 00349281121883 | 7/18/2024 | 197 | Influenza, high-dose, quadrivalent, PF | PMC |
49281-0122-65 | FLUZONE High-Dose Quadrivalent Northern Hemisphere | Sanofi Pasteur Inc. | 7/1/2022 | 6/30/2023 | 00349281122651 | 7/18/2024 | 49281-0122-88 | False | 00349281122880 | 7/18/2024 | 197 | Influenza, high-dose, quadrivalent, PF | PMC |
49281-0123-65 | Fluzone High-Dose Quadrivalent Northern Hemisphere | Sanofi Pasteur Inc. | 6/30/2023 | 6/30/2024 | 00349281123658 | 9/19/2024 | 49281-0123-88 | False | 00349281123887 | 9/19/2024 | 197 | Influenza, high-dose, quadrivalent, PF | PMC |
49281-0124-65 | FLUZONE HIGH DOSE NORTHERN HEMISPHERE | Sanofi Pasteur Inc. | 7/1/2024 | 00349281124655 | 9/27/2024 | 49281-0124-88 | False | 00349281124884 | 9/27/2024 | 135 | Influenza, high-dose, trivalent, PF | PMC | |
49281-0181-25 | FLUZONE QUADRIVALENT SOUTHERN HEMISPHERE | Sanofi Pasteur Inc. | 9/30/2019 | 12/31/2020 | 7/18/2024 | 49281-0181-00 | False | 7/18/2024 | 200 | influenza, Southern Hemisphere, pediatric, preservative free | PMC | ||
49281-0182-25 | FLUZONE QUADRIVALENT SOUTHERN HEMISPHERE | Sanofi Pasteur Inc. | 2/4/2021 | 12/31/2021 | 00349281182259 | 7/18/2024 | 49281-0182-00 | False | 00349281182006 | 7/18/2024 | 200 | influenza, Southern Hemisphere, pediatric, preservative free | PMC |
49281-0215-10 | TENIVAC | Sanofi Pasteur Inc. | 12/8/2010 | 00349281215100 | 2/2/2023 | 49281-0215-58 | False | 00349281215582 | 2/2/2023 | 113 | Td (adult), 5 Lf tetanus toxoid, preservative free, adsorbed | PMC | |
49281-0215-15 | TENIVAC | Sanofi Pasteur Inc. | 12/8/2010 | 00349281215155 | 2/2/2023 | 49281-0215-88 | False | 00349281215889 | 2/22/2023 | 113 | Td (adult), 5 Lf tetanus toxoid, preservative free, adsorbed | PMC | |
49281-0225-10 | DIPHTHERIA AND TETANUS TOXOIDS ADSORBED | Sanofi Pasteur Inc. | 3/29/2010 | 00349281225109 | 1/31/2022 | 49281-0225-58 | False | 00349281225581 | 2/1/2023 | 28 | DT (pediatric) | PMC | |
49281-0250-51 | IMOVAX RABIES | Sanofi Pasteur Inc. | 9/30/2013 | 12/7/2021 | 00349281250514 | 12/13/2021 | 49281-0248-58 | False | 00349281248580 | 5/16/2022 | 175 | Rabies - IM Diploid cell culture | PMC |
49281-0252-51 | IMOVAX RABIES | Sanofi Pasteur Inc. | 10/25/2019 | 00349281252518 | 2/2/2023 | 49281-0246-58 | False | 00349281246586 | 2/2/2023 | 175 | Rabies - IM Diploid cell culture | PMC | |
49281-0278-10 | DIPHTHERIA AND TETANUS TOXOIDS ADSORBED | Sanofi Pasteur Inc. | 9/18/1984 | 3/18/2013 | 1/29/2018 | 49281-0278-10 | True | 1/29/2018 | 28 | DT (pediatric) | PMC | ||
49281-0286-01 | DAPTACEL | Sanofi Pasteur Inc. | 5/14/2002 | 00349281286018 | 4/24/2023 | 49281-0286-58 | False | 00349281286582 | 2/1/2023 | 106 | DTaP, 5 pertussis antigens | PMC | |
49281-0286-05 | DAPTACEL | Sanofi Pasteur Inc. | 5/14/2002 | 00349281286056 | 1/31/2022 | 49281-0286-58 | False | 00349281286582 | 2/1/2023 | 106 | DTaP, 5 pertussis antigens | PMC | |
49281-0286-10 | DAPTACEL | Sanofi Pasteur Inc. | 5/14/2002 | 00349281286100 | 1/31/2022 | 49281-0286-58 | False | 00349281286582 | 2/1/2023 | 106 | DTaP, 5 pertussis antigens | PMC | |
49281-0291-10 | DECAVAC | Sanofi Pasteur Inc. | 3/24/2004 | 12/31/2012 | 5/30/2018 | 49281-0291-10 | True | 5/30/2018 | 113 | Td (adult), 5 Lf tetanus toxoid, preservative free, adsorbed | PMC | ||
49281-0291-83 | DECAVAC | Sanofi Pasteur Inc. | 3/24/2004 | 12/31/2012 | 5/30/2018 | 49281-0291-83 | True | 6/8/2018 | 113 | Td (adult), 5 Lf tetanus toxoid, preservative free, adsorbed | PMC | ||
49281-0298-10 | TRIPEDIA | Sanofi Pasteur Inc. | 8/20/1992 | 3/13/2013 | 1/29/2018 | 49281-0298-10 | True | 1/29/2018 | 20 | DTaP | PMC | ||
49281-0320-50 | FLUZONE QUADRIVALENT SOUTHERN HEMISPHERE | Sanofi Pasteur Inc. | 9/30/2019 | 12/31/2020 | 7/18/2024 | 49281-0320-88 | False | 7/18/2024 | 201 | influenza, Southern Hemisphere, preservative free | PMC | ||
49281-0321-50 | FLUZONE QUADRIVALENT SOUTHERN HEMISPHERE | Sanofi Pasteur Inc. | 2/4/2021 | 12/31/2021 | 00349281321504 | 7/18/2024 | 49281-0321-88 | False | 00349281321887 | 7/18/2024 | 201 | influenza, Southern Hemisphere, preservative free | PMC |
49281-0322-50 | FLUZONE QUADRIVALENT SOUTHERN HEMISPHERE | Sanofi Pasteur Inc. | 2/15/2022 | 12/31/2022 | 00349281322501 | 7/18/2024 | 49281-0322-88 | False | 00349281322884 | 7/18/2024 | 201 | influenza, Southern Hemisphere, preservative free | PMC |
49281-0323-50 | FLUZONE QUADRIVALENT SOUTHERN HEMISPHERE | Sanofi Pasteur Inc. | 2/13/2023 | 12/31/2023 | 7/18/2024 | 49281-0323-88 | False | 7/18/2024 | 201 | influenza, Southern Hemisphere, preservative free | PMC | ||
49281-0324-50 | FLUZONE QUADRIVALENT SOUTHERN HEMISPHERE | Sanofi Pasteur Inc. | 2/14/2024 | 00349281324505 | 9/19/2024 | 49281-0324-88 | False | 00349281324888 | 9/19/2024 | 201 | influenza, Southern Hemisphere, preservative free | PMC | |
49281-0336-15 | FLUZONE QUADRIVALENT SOUTHERN HEMISPHERE | Sanofi Pasteur Inc. | 9/30/2019 | 12/31/2020 | 7/18/2024 | 49281-0336-78 | False | 7/18/2024 | 202 | influenza, Southern Hemisphere, quadrivalent, with preservative | PMC | ||
49281-0337-15 | FLUZONE QUADRIVALENT SOUTHERN HEMISPHERE | Sanofi Pasteur Inc. | 2/4/2021 | 12/31/2021 | 00349281337154 | 7/18/2024 | 49281-0337-78 | False | 00349281337789 | 7/18/2024 | 202 | influenza, Southern Hemisphere, quadrivalent, with preservative | PMC |
49281-0339-15 | FLUZONE QUADRIVALENT SOUTHERN HEMISPHERE | Sanofi Pasteur Inc. | 2/15/2022 | 12/31/2022 | 00349281339158 | 7/18/2024 | 49281-0339-78 | False | 00349281339783 | 7/18/2024 | 202 | influenza, Southern Hemisphere, quadrivalent, with preservative | PMC |
49281-0355-15 | FLUZONE QUADRIVALENT SOUTHERN HEMISPHERE | Sanofi Pasteur Inc. | 2/13/2023 | 12/31/2023 | 7/18/2024 | 49281-0355-78 | False | 7/18/2024 | 202 | influenza, Southern Hemisphere, quadrivalent, with preservative | PMC | ||
49281-0379-50 | FLUZONE High-Dose Quadrivalent Southern Hemisphere | Sanofi Pasteur Inc. | 2/13/2023 | 12/31/2023 | 7/18/2024 | 49281-0379-88 | False | 7/18/2024 | 231 | influenza, Southern Hemisphere, high-dose, quadrivalent | PMC | ||
49281-0386-15 | FLUZONE | Sanofi Pasteur Inc. | 7/23/2010 | 6/30/2011 | 1/29/2018 | 49281-0386-15 | True | 00349281386152 | 7/4/2018 | 141 | Influenza, split virus, trivalent, preservative | PMC | |
49281-0387-65 | FLUZONE | Sanofi Pasteur Inc. | 7/23/2010 | 6/30/2011 | 1/29/2018 | 49281-0387-65 | True | 00349281387654 | 7/4/2018 | 135 | Influenza, high-dose, trivalent, PF | PMC | |
49281-0388-15 | FLUZONE | Sanofi Pasteur Inc. | 7/1/2011 | 6/30/2012 | 1/29/2018 | 49281-0388-15 | True | 00349281388156 | 1/29/2018 | 141 | Influenza, split virus, trivalent, preservative | PMC | |
49281-0389-65 | FLUZONE HIGH DOSE | Sanofi Pasteur Inc. | 7/1/2011 | 6/30/2012 | 2/27/2018 | 49281-0389-65 | True | 00349281389658 | 7/4/2018 | 135 | Influenza, high-dose, trivalent, PF | PMC | |
49281-0390-15 | FLUZONE | Sanofi Pasteur Inc. | 7/2/2012 | 6/30/2013 | 12/7/2017 | 49281-0390-15 | True | 00349281390159 | 7/4/2018 | 141 | Influenza, split virus, trivalent, preservative | PMC | |
49281-0391-65 | FLUZONE High-Dose | Sanofi Pasteur Inc. | 7/2/2012 | 6/30/2013 | 12/7/2017 | 49281-0391-65 | True | 00349281391651 | 7/4/2018 | 135 | Influenza, high-dose, trivalent, PF | PMC | |
49281-0392-15 | FLUZONE | Sanofi Pasteur Inc. | 6/28/2013 | 6/30/2014 | 12/7/2017 | 49281-0392-78 | False | 00349281392788 | 11/20/2017 | 141 | Influenza, split virus, trivalent, preservative | PMC | |
49281-0393-65 | FLUZONE High-Dose | Sanofi Pasteur Inc. | 6/28/2013 | 6/30/2014 | 12/7/2017 | 49281-0393-88 | False | 00349281393884 | 11/20/2017 | 135 | Influenza, high-dose, trivalent, PF | PMC | |
49281-0394-15 | FLUZONE | Sanofi Pasteur Inc. | 6/27/2014 | 6/30/2015 | 7/6/2018 | 49281-0394-78 | False | 7/4/2018 | 141 | Influenza, split virus, trivalent, preservative | PMC | ||
49281-0395-65 | FLUZONE High-Dose | Sanofi Pasteur Inc. | 6/27/2014 | 6/30/2015 | 6/27/2018 | 49281-0395-88 | False | 7/4/2018 | 135 | Influenza, high-dose, trivalent, PF | PMC | ||
49281-0396-15 | FLUZONE | Sanofi Pasteur Inc. | 6/26/2015 | 6/30/2016 | 12/7/2017 | 49281-0396-78 | False | 00349281396786 | 11/20/2017 | 141 | Influenza, split virus, trivalent, preservative | PMC | |
49281-0397-65 | FLUZONE High-Dose | Sanofi Pasteur Inc. | 6/26/2015 | 6/30/2016 | 12/7/2017 | 49281-0397-88 | False | 00349281397882 | 11/20/2017 | 135 | Influenza, high-dose, trivalent, PF | PMC | |
49281-0398-15 | FLUZONE QUADRIVALENT SOUTHERN HEMISPHERE | Sanofi Pasteur Inc. | 2/14/2024 | 7/18/2024 | 49281-0398-78 | False | 7/18/2024 | 202 | influenza, Southern Hemisphere, quadrivalent, with preservative | PMC | |||
49281-0399-65 | FLUZONE High-Dose | Sanofi Pasteur Inc. | 7/1/2016 | 6/30/2017 | 7/11/2018 | 49281-0399-88 | False | 5/30/2018 | 135 | Influenza, high-dose, trivalent, PF | PMC | ||
49281-0400-05 | Adacel | Sanofi Pasteur Inc. | 6/10/2005 | 00349281400056 | 4/24/2023 | 49281-0400-58 | False | 00349281400582 | 2/1/2023 | 115 | Tdap | PMC | |
49281-0400-10 | Adacel | Sanofi Pasteur Inc. | 6/10/2005 | 00349281400100 | 1/31/2022 | 49281-0400-58 | False | 00349281400582 | 2/1/2023 | 115 | Tdap | PMC | |
49281-0400-15 | Adacel | Sanofi Pasteur Inc. | 10/1/2013 | 1/20/2021 | 1/28/2021 | 49281-0400-88 | False | 00349281400889 | 1/25/2021 | 115 | Tdap | PMC | |
49281-0400-20 | Adacel | Sanofi Pasteur Inc. | 6/10/2005 | 00349281400209 | 1/31/2022 | 49281-0400-89 | False | 00349281400896 | 2/1/2023 | 115 | Tdap | PMC | |
49281-0401-65 | FLUZONE High-Dose | Sanofi Pasteur Inc. | 7/1/2017 | 6/30/2018 | 7/9/2018 | 49281-0401-88 | False | 7/9/2018 | 135 | Influenza, high-dose, trivalent, PF | PMC | ||
49281-0403-65 | FLUZONE High-Dose | Sanofi Pasteur Inc. | 6/29/2018 | 6/30/2019 | 5/3/2023 | 49281-0403-88 | False | 00349281403880 | 5/3/2023 | 135 | Influenza, high-dose, trivalent, PF | PMC | |
49281-0405-65 | FLUZONE High-Dose | Sanofi Pasteur Inc. | 7/1/2019 | 6/30/2020 | 7/18/2024 | 49281-0405-88 | False | 00349281405884 | 7/18/2024 | 135 | Influenza, high-dose, trivalent, PF | PMC | |
49281-0413-10 | FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 6/10/2013 | 6/30/2014 | 12/7/2017 | 49281-0413-58 | False | 00349281413582 | 11/20/2017 | 150 | Influenza, split virus, quadrivalent, PF | PMC | |
49281-0413-50 | FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 6/10/2013 | 6/30/2014 | 12/7/2017 | 49281-0413-88 | False | 00349281413889 | 11/20/2017 | 150 | Influenza, split virus, quadrivalent, PF | PMC | |
49281-0414-10 | FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 6/27/2014 | 6/30/2015 | 7/13/2018 | 49281-0414-58 | False | 00349281414589 | 7/5/2018 | 150 | Influenza, split virus, quadrivalent, PF | PMC | |
49281-0414-50 | FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 6/27/2014 | 6/30/2015 | 7/12/2018 | 49281-0414-88 | False | 00349281414886 | 7/5/2018 | 150 | Influenza, split virus, quadrivalent, PF | PMC | |
49281-0415-10 | FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 6/26/2015 | 6/30/2016 | 7/12/2018 | 49281-0415-58 | False | 00349281415586 | 5/30/2018 | 150 | Influenza, split virus, quadrivalent, PF | PMC | |
49281-0416-10 | FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 7/1/2016 | 6/30/2017 | 7/11/2018 | 49281-0416-58 | False | 5/30/2018 | 150 | Influenza, split virus, quadrivalent, PF | PMC | ||
49281-0416-50 | FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 7/1/2016 | 6/30/2017 | 7/11/2018 | 49281-0416-88 | False | 5/30/2018 | 150 | Influenza, split virus, quadrivalent, PF | PMC | ||
49281-0417-10 | FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 7/1/2017 | 6/30/2018 | 7/13/2018 | 49281-0417-58 | False | 00349281417580 | 7/9/2018 | 150 | Influenza, split virus, quadrivalent, PF | PMC | |
49281-0417-50 | FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 7/1/2017 | 6/30/2018 | 7/13/2018 | 49281-0417-88 | False | 00349281417887 | 7/9/2018 | 150 | Influenza, split virus, quadrivalent, PF | PMC | |
49281-0418-10 | FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 6/29/2018 | 6/30/2019 | 7/16/2019 | 49281-0418-58 | False | 00349281418587 | 7/16/2019 | 150 | Influenza, split virus, quadrivalent, PF | PMC | |
49281-0418-50 | FLUZONE QUADRIVALENT NORTHERN HEMISPHERE | Sanofi Pasteur Inc. | 6/29/2018 | 6/30/2019 | 8/6/2024 | 49281-0418-88 | False | 00349281418884 | 8/6/2024 | 150 | Influenza, split virus, quadrivalent, PF | PMC | |
49281-0419-10 | FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 7/1/2019 | 6/30/2020 | 7/18/2024 | 49281-0419-58 | False | 00349281419584 | 7/18/2024 | 150 | Influenza, split virus, quadrivalent, PF | PMC | |
49281-0419-50 | FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 7/1/2019 | 6/30/2020 | 7/18/2024 | 49281-0419-88 | False | 00349281419881 | 7/18/2024 | 150 | Influenza, split virus, quadrivalent, PF | PMC | |
49281-0420-10 | FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 7/1/2020 | 6/30/2021 | 7/18/2024 | 49281-0420-58 | False | 7/18/2024 | 150 | Influenza, split virus, quadrivalent, PF | PMC | ||
49281-0420-50 | FLUZONE QUADRIVALENT NORTHERN HEMISPHERE | Sanofi Pasteur Inc. | 7/1/2020 | 6/30/2021 | 8/6/2024 | 49281-0420-88 | False | 8/6/2024 | 150 | Influenza, split virus, quadrivalent, PF | PMC | ||
49281-0421-10 | FLUZONE QUADRIVALENT NORTHERN HEMISPHERE | Sanofi Pasteur Inc. | 7/1/2021 | 6/30/2022 | 00349281421105 | 8/6/2024 | 49281-0421-58 | False | 00349281421587 | 8/6/2024 | 150 | Influenza, split virus, quadrivalent, PF | PMC |
49281-0421-50 | FLUZONE QUADRIVALENT NORTHERN HEMISPHERE | Sanofi Pasteur Inc. | 7/2/2021 | 6/30/2022 | 00349281421501 | 8/6/2024 | 49281-0421-88 | False | 00349281421884 | 8/6/2024 | 150 | Influenza, split virus, quadrivalent, PF | PMC |
49281-0422-10 | FLUZONE QUADRIVALENT NORTHERN HEMISPHERE | Sanofi Pasteur Inc. | 7/1/2022 | 6/30/2023 | 00349281422102 | 8/6/2024 | 49281-0422-58 | False | 00349281422584 | 8/6/2024 | 150 | Influenza, split virus, quadrivalent, PF | PMC |
49281-0422-50 | FLUZONE QUADRIVALENT NORTHERN HEMISPHERE | Sanofi Pasteur Inc. | 7/1/2022 | 6/30/2023 | 00349281422508 | 8/6/2024 | 49281-0422-88 | False | 00349281422881 | 8/6/2024 | 150 | Influenza, split virus, quadrivalent, PF | PMC |
49281-0423-50 | Fluzone Quadrivalent Northern Hemisphere | Sanofi Pasteur Inc. | 6/30/2023 | 6/30/2024 | 00349281423505 | 9/19/2024 | 49281-0423-88 | False | 00349281423888 | 9/19/2024 | 150 | Influenza, split virus, quadrivalent, PF | PMC |
49281-0424-50 | FLUZONE TRIVALENT NORTHERN HEMISPHERE | Sanofi Pasteur Inc. | 7/1/2024 | 00349281424502 | 9/27/2024 | 49281-0424-88 | False | 00349281424885 | 9/27/2024 | 140 | Influenza, split virus, trivalent, PF | PMC | |
49281-0489-01 | MENOMUNE - A/C/Y/W-135 COMBINED | Sanofi Pasteur Inc. | 11/23/1981 | 4/30/2019 | 5/29/2019 | 49281-0487-58 | False | 00349281487583 | 5/21/2019 | 32 | meningococcal MPSV4 | PMC | |
49281-0489-91 | MENOMUNE - A/C/Y/W-135 COMBINED | Sanofi Pasteur Inc. | 11/23/1981 | 9/30/2017 | 7/12/2018 | 49281-0488-78 | False | 00349281488788 | 5/21/2019 | 32 | meningococcal MPSV4 | PMC | |
49281-0510-05 | PENTACEL | Sanofi Pasteur Inc. | 6/20/2008 | 11/9/2022 | 00349281510052 | 11/29/2022 | 49281-0545-15 | False | 00349281545153 | 8/22/2019 | 120 | DTaP-Hib-IPV | PMC |
49281-0510-05 | PENTACEL | Sanofi Pasteur Inc. | 6/20/2008 | 11/9/2022 | 00349281510052 | 11/29/2022 | 49281-0560-05 | False | 00349281560057 | 11/29/2022 | 120 | DTaP-Hib-IPV | PMC |
49281-0510-05 | PENTACEL | Sanofi Pasteur Inc. | 6/20/2008 | 11/9/2022 | 00349281510052 | 11/29/2022 | 49281-0548-58 | False | 00349281548581 | 11/29/2022 | 120 | DTaP-Hib-IPV | PMC |
49281-0511-05 | PENTACEL | Sanofi Pasteur Inc. | 1/1/2020 | 00349281511059 | 11/8/2021 | 49281-0561-01 | False | 00349281561016 | 11/8/2021 | 120 | DTaP-Hib-IPV | PMC | |
49281-0511-05 | PENTACEL | Sanofi Pasteur Inc. | 1/1/2020 | 00349281511059 | 11/8/2021 | 49281-0544-58 | False | 00349281544583 | 11/8/2021 | 120 | DTaP-Hib-IPV | PMC | |
49281-0513-25 | FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 6/10/2013 | 6/30/2014 | 12/7/2017 | 49281-0513-00 | False | 00349281513008 | 11/20/2017 | 161 | Influenza, injectable,quadrivalent, preservative free, pediatric | PMC | |
49281-0514-25 | FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 6/27/2014 | 6/30/2015 | 7/13/2018 | 49281-0514-00 | False | 00349281514005 | 7/5/2018 | 161 | Influenza, injectable,quadrivalent, preservative free, pediatric | PMC | |
49281-0516-25 | FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 7/1/2016 | 6/30/2017 | 7/11/2018 | 49281-0516-00 | False | 5/30/2018 | 161 | Influenza, injectable,quadrivalent, preservative free, pediatric | PMC | ||
49281-0517-25 | FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 7/1/2017 | 6/30/2018 | 7/13/2018 | 49281-0517-00 | False | 00349281517006 | 7/9/2018 | 161 | Influenza, injectable,quadrivalent, preservative free, pediatric | PMC | |
49281-0518-25 | FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 6/29/2018 | 6/30/2019 | 7/16/2019 | 49281-0518-00 | False | 00349281518003 | 7/16/2019 | 161 | Influenza, injectable,quadrivalent, preservative free, pediatric | PMC | |
49281-0519-25 | FLUZONE QUADRIVALENT NORTHERN HEMISPHERE | Sanofi Pasteur Inc. | 7/1/2019 | 6/30/2020 | 8/6/2024 | 49281-0519-00 | False | 00349281519000 | 8/6/2024 | 161 | Influenza, injectable,quadrivalent, preservative free, pediatric | PMC | |
49281-0520-25 | FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 7/1/2020 | 6/30/2021 | 7/18/2024 | 49281-0520-00 | False | 7/18/2024 | 161 | Influenza, injectable,quadrivalent, preservative free, pediatric | PMC | ||
49281-0521-25 | FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 7/2/2021 | 6/30/2022 | 00349281521256 | 7/18/2024 | 49281-0521-00 | False | 00349281521003 | 7/18/2024 | 161 | Influenza, injectable,quadrivalent, preservative free, pediatric | PMC |
49281-0545-03 | ActHIB | Sanofi Pasteur Inc. | 5/31/2016 | 00349281545030 | 11/8/2021 | 49281-0547-58 | False | 00349281547584 | 10/30/2015 | 48 | Hib (PRP-T) | PMC | |
49281-0545-05 | ActHIB | Sanofi Pasteur Inc. | 3/30/1993 | 11/28/2016 | 7/12/2018 | 49281-0547-58 | False | 00349281547584 | 10/30/2015 | 48 | Hib (PRP-T) | PMC | |
49281-0562-10 | QUADRACEL | Sanofi Pasteur Inc. | 3/24/2015 | 10/11/2024 | 00349281562105 | 10/16/2024 | 49281-0562-58 | False | 00349281562587 | 10/16/2024 | 130 | DTaP-IPV | PMC |
49281-0564-10 | QUADRACEL | Sanofi Pasteur Inc. | 2/6/2020 | 00349281564109 | 9/19/2024 | 49281-0564-58 | False | 00349281564581 | 9/19/2024 | 130 | DTaP-IPV | PMC | |
49281-0564-15 | QUADRACEL | Sanofi Pasteur Inc. | 2/4/2022 | 00349281564154 | 10/17/2022 | 49281-0564-88 | False | 00349281564888 | 2/1/2023 | 130 | DTaP-IPV | PMC | |
49281-0574-15 | BEYFORTUS | Sanofi Pasteur Inc. | 7/18/2023 | 00349281574153 | 9/19/2024 | 49281-0574-88 | False | 00349281574887 | 9/19/2024 | 307 | RSV, mAb, nirsevimab-alip, 1 mL, neonate to 24 months | PMC | |
49281-0575-15 | BEYFORTUS | Sanofi Pasteur Inc. | 7/18/2023 | 00349281575150 | 9/19/2024 | 49281-0575-00 | False | 00349281575006 | 9/19/2024 | 306 | RSV, mAb, nirsevimab-alip, 0.5 mL, neonate to 24 months | PMC | |
49281-0589-05 | Menactra | Sanofi Pasteur Inc. | 1/14/2005 | 10/1/2022 | 00349281589058 | 6/11/2024 | 49281-0589-58 | False | 00349281589584 | 6/11/2024 | 114 | meningococcal MCV4P | PMC |
49281-0590-01 | MenQuadfi | Sanofi Pasteur Inc. | 4/23/2020 | 00349281590016 | 9/19/2024 | 49281-0590-58 | False | 00349281590580 | 4/23/2024 | 203 | meningococcal conjugate quadrivalent, MenACWY-TT (MCV4) | PMC | |
49281-0590-05 | MenQuadfi | Sanofi Pasteur Inc. | 4/23/2020 | 00349281590054 | 4/23/2024 | 49281-0590-58 | False | 00349281590580 | 4/23/2024 | 203 | meningococcal conjugate quadrivalent, MenACWY-TT (MCV4) | PMC | |
49281-0590-10 | MenQuadfi | Sanofi Pasteur Inc. | 4/23/2020 | 5/9/2024 | 49281-0590-58 | False | 00349281590580 | 4/23/2024 | 203 | meningococcal conjugate quadrivalent, MenACWY-TT (MCV4) | PMC | ||
49281-0605-01 | Dengvaxia | Sanofi Pasteur Inc. | 5/1/2019 | 00349281605017 | 10/24/2023 | 49281-0606-58 | False | 00349281606588 | 10/24/2023 | 56 | dengue fever tetravalent | PMC | |
49281-0618-20 | ANTIGEN COMPONENT | Sanofi Pasteur Inc. | 4/1/2022 | 10/31/2022 | 1/10/2023 | 49281-0618-78 | False | 1/10/2023 | 225 | COVID-19, D614, recomb, preS dTM, AS03 adjuvant add, PF, 5mcg/0.5mL | PMC | ||
49281-0621-15 | FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 6/27/2014 | 6/30/2015 | 7/6/2018 | 49281-0621-78 | False | 11/20/2017 | 158 | Influenza, split virus, quadrivalent, preservative | PMC | ||
49281-0625-15 | FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 7/1/2016 | 6/30/2017 | 7/11/2018 | 49281-0625-78 | False | 5/30/2018 | 158 | Influenza, split virus, quadrivalent, preservative | PMC | ||
49281-0627-15 | FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 7/1/2017 | 6/30/2018 | 7/13/2018 | 49281-0627-78 | False | 7/9/2018 | 158 | Influenza, split virus, quadrivalent, preservative | PMC | ||
49281-0629-15 | FLUZONE QUADRIVALENT NORTHERN HEMISPHERE | Sanofi Pasteur Inc. | 6/29/2018 | 6/30/2019 | 8/6/2024 | 49281-0629-78 | False | 00349281629785 | 8/6/2024 | 158 | Influenza, split virus, quadrivalent, preservative | PMC | |
49281-0631-15 | FLUZONE QUADRIVALENT NORTHERN HEMISPHERE | Sanofi Pasteur Inc. | 7/1/2019 | 6/30/2020 | 8/6/2024 | 49281-0631-78 | False | 00349281631788 | 8/6/2024 | 158 | Influenza, split virus, quadrivalent, preservative | PMC | |
49281-0633-15 | FLUZONE QUADRIVALENT NORTHERN HEMISPHERE | Sanofi Pasteur Inc. | 7/1/2020 | 6/30/2021 | 8/6/2024 | 49281-0633-78 | False | 8/6/2024 | 158 | Influenza, split virus, quadrivalent, preservative | PMC | ||
49281-0635-15 | FLUZONE QUADRIVALENT NORTHERN HEMISPHERE | Sanofi Pasteur Inc. | 7/2/2021 | 6/30/2022 | 00349281635151 | 8/6/2024 | 49281-0635-78 | False | 00349281635786 | 8/6/2024 | 158 | Influenza, split virus, quadrivalent, preservative | PMC |
49281-0637-15 | FLUZONE QUADRIVALENT NORTHERN HEMISPHERE | Sanofi Pasteur Inc. | 7/1/2022 | 6/30/2023 | 00349281637155 | 8/6/2024 | 49281-0637-78 | False | 00349281637780 | 8/6/2024 | 158 | Influenza, split virus, quadrivalent, preservative | PMC |
49281-0639-15 | Fluzone Quadrivalent Northern Hemisphere | Sanofi Pasteur Inc. | 6/30/2023 | 6/30/2024 | 00349281639159 | 9/19/2024 | 49281-0639-78 | False | 00349281639784 | 9/19/2024 | 158 | Influenza, split virus, quadrivalent, preservative | PMC |
49281-0640-15 | INFLUENZA A (H1N1) 2009 MONOVALENT VACCINE | Sanofi Pasteur Inc. | 9/15/2009 | 3/3/2017 | 5/30/2018 | 49281-0640-15 | True | 6/8/2018 | 127 | Novel influenza-H1N1-09 | PMC | ||
49281-0641-15 | FLUZONE TRIVALENT NORTHERN HEMISPHERE | Sanofi Pasteur Inc. | 7/1/2024 | 00349281641152 | 9/27/2024 | 49281-0641-78 | False | 00349281641787 | 9/27/2024 | 141 | Influenza, split virus, trivalent, preservative | PMC | |
49281-0650-10 | INFLUENZA A (H1N1) 2009 MONOVALENT VACCINE | Sanofi Pasteur Inc. | 9/15/2009 | 6/30/2010 | 10/15/2019 | 49281-0650-10 | True | 10/15/2019 | 126 | Novel influenza-H1N1-09, preservative-free | PMC | ||
49281-0650-25 | INFLUENZA A (H1N1) 2009 MONOVALENT VACCINE | Sanofi Pasteur Inc. | 9/15/2009 | 6/30/2010 | 10/15/2019 | 49281-0650-25 | True | 10/15/2019 | 126 | Novel influenza-H1N1-09, preservative-free | PMC | ||
49281-0650-50 | INFLUENZA A (H1N1) 2009 MONOVALENT VACCINE | Sanofi Pasteur Inc. | 9/15/2009 | 6/30/2010 | 10/15/2019 | 49281-0650-50 | True | 10/15/2019 | 126 | Novel influenza-H1N1-09, preservative-free | PMC | ||
49281-0650-70 | INFLUENZA A (H1N1) 2009 MONOVALENT VACCINE | Sanofi Pasteur Inc. | 9/15/2009 | 6/30/2010 | 10/15/2019 | 49281-0650-70 | True | 10/15/2019 | 126 | Novel influenza-H1N1-09, preservative-free | PMC | ||
49281-0650-90 | INFLUENZA A (H1N1) 2009 MONOVALENT VACCINE | Sanofi Pasteur Inc. | 9/15/2009 | 6/30/2010 | 10/15/2019 | 49281-0650-90 | True | 10/15/2019 | 126 | Novel influenza-H1N1-09, preservative-free | PMC | ||
49281-0703-55 | FLUZONE INTRADERMAL | Sanofi Pasteur Inc. | 7/1/2011 | 6/30/2012 | 1/29/2018 | 49281-0703-55 | True | 00349281703553 | 2/27/2018 | 144 | influenza, seasonal, intradermal, preservative free | PMC | |
49281-0705-55 | FLUZONE | Sanofi Pasteur Inc. | 7/2/2012 | 6/30/2013 | 12/7/2017 | 49281-0705-55 | True | 00349281705557 | 7/5/2018 | 144 | influenza, seasonal, intradermal, preservative free | PMC | |
49281-0707-55 | FLUZONE | Sanofi Pasteur Inc. | 6/28/2013 | 6/30/2014 | 12/7/2017 | 49281-0707-48 | False | 00349281707483 | 2/22/2018 | 144 | influenza, seasonal, intradermal, preservative free | PMC | |
49281-0708-40 | FLUZONE INTRADERMAL QUADRIVALENT | Sanofi Pasteur Inc. | 12/11/2014 | 6/30/2015 | 12/7/2017 | 49281-0708-48 | False | 7/5/2018 | 166 | influenza, intradermal, quadrivalent, preservative free | PMC | ||
49281-0709-55 | FLUZONE Intradermal | Sanofi Pasteur Inc. | 6/27/2014 | 6/30/2015 | 7/12/2018 | 49281-0709-48 | False | 00349281709487 | 7/5/2018 | 144 | influenza, seasonal, intradermal, preservative free | PMC | |
49281-0710-40 | FLUZONE INTRADERMAL QUADRIVALENT | Sanofi Pasteur Inc. | 7/1/2016 | 6/30/2017 | 7/11/2018 | 49281-0710-48 | False | 5/30/2018 | 166 | influenza, intradermal, quadrivalent, preservative free | PMC | ||
49281-0712-40 | FLUZONE INTRADERMAL QUADRIVALENT | Sanofi Pasteur Inc. | 7/1/2017 | 6/30/2018 | 7/13/2018 | 49281-0712-48 | False | 00349281712487 | 7/9/2018 | 166 | influenza, intradermal, quadrivalent, preservative free | PMC | |
49281-0718-10 | Flublok Quadrivalent | Sanofi Pasteur Inc. | 6/29/2018 | 6/30/2019 | 7/16/2019 | 49281-0718-88 | False | 00349281718885 | 7/16/2019 | 185 | Influenza, recombinant, quadrivalent, PF | PMC | |
49281-0719-10 | Flublok Quadrivalent | Sanofi Pasteur Inc. | 7/1/2019 | 6/30/2020 | 7/18/2024 | 49281-0719-88 | False | 00349281719882 | 7/18/2024 | 185 | Influenza, recombinant, quadrivalent, PF | PMC | |
49281-0720-10 | Flublok Quadrivalent Northern Hemisphere | Sanofi Pasteur Inc. | 7/1/2020 | 6/30/2021 | 7/18/2024 | 49281-0720-88 | False | 7/18/2024 | 185 | Influenza, recombinant, quadrivalent, PF | PMC | ||
49281-0721-10 | Flublok Quadrivalent Northern Hemisphere | Sanofi Pasteur Inc. | 7/2/2021 | 6/30/2022 | 00349281721106 | 7/18/2024 | 49281-0721-88 | False | 00349281721885 | 7/18/2024 | 185 | Influenza, recombinant, quadrivalent, PF | PMC |
49281-0722-10 | Flublok Quadrivalent Northern Hemisphere | Sanofi Pasteur Inc. | 7/1/2022 | 6/30/2023 | 00349281722103 | 7/18/2024 | 49281-0722-88 | False | 00349281722882 | 7/18/2024 | 185 | Influenza, recombinant, quadrivalent, PF | PMC |
49281-0723-10 | Flublok Quadrivalent Northern Hemisphere | Sanofi Pasteur Inc. | 6/30/2023 | 6/30/2024 | 7/18/2024 | 49281-0723-88 | False | 00349281723889 | 9/19/2024 | 185 | Influenza, recombinant, quadrivalent, PF | PMC | |
49281-0724-10 | FLUBLOK TRIVALENT NORTHERN HEMISPHERE | Sanofi Pasteur Inc. | 7/1/2024 | 00349281724107 | 9/17/2024 | 49281-0724-88 | False | 00349281724886 | 9/17/2024 | 155 | Influenza, recombinant, trivalent, PF | PMC | |
49281-0790-20 | Typhim Vi | Sanofi Pasteur Inc. | 11/28/1994 | 00349281790201 | 2/2/2023 | 49281-0790-38 | False | 00349281790386 | 2/2/2023 | 101 | typhoid, ViCPs | PMC | |
49281-0790-51 | Typhim Vi | Sanofi Pasteur Inc. | 11/28/1994 | 00349281790515 | 2/2/2023 | 49281-0790-88 | False | 00349281790881 | 2/2/2023 | 101 | typhoid, ViCPs | PMC | |
49281-0800-83 | TETANUS TOXOID ADSORBED | Sanofi Pasteur Inc. | 9/23/2005 | 5/5/2017 | 5/30/2018 | 49281-0800-83 | True | 5/30/2018 | 35 | tetanus toxoid, adsorbed | PMC | ||
49281-0820-10 | TETANUS TOXOID ADSORBED | Sanofi Pasteur Inc. | 9/23/2005 | 5/5/2017 | 5/30/2018 | 49281-0820-10 | True | 5/30/2018 | 35 | tetanus toxoid, adsorbed | PMC | ||
49281-0860-10 | IPOL | Sanofi Pasteur Inc. | 12/21/1990 | 00349281860102 | 11/8/2021 | 49281-0860-78 | False | 00349281860782 | 2/1/2023 | 10 | IPV | PMC | |
49281-0860-10 | IPOL | Sanofi Pasteur Inc. | 12/21/1990 | 00349281860102 | 11/8/2021 | 49281-0860-88 | False | 00349281860881 | 6/8/2018 | 10 | IPV | PMC | |
49281-0860-55 | IPOL | Sanofi Pasteur Inc. | 12/21/1990 | 6/16/2011 | 00349281860553 | 11/8/2021 | 49281-0860-78 | False | 00349281860782 | 2/1/2023 | 10 | IPV | PMC |
49281-0913-01 | STAMARIL | Sanofi Pasteur Inc. | 9/27/2016 | 00349281913013 | 10/26/2023 | 49281-0913-01 | True | 00349281913013 | 9/27/2024 | 183 | Yellow fever vaccine live - alt | PMC | |
49281-0915-01 | YF-VAX | Sanofi Pasteur Inc. | 5/22/1953 | 00349281915017 | 2/2/2023 | 49281-0915-58 | False | 00349281915581 | 2/2/2023 | 37 | yellow fever live | PMC | |
49281-0915-05 | YF-VAX | Sanofi Pasteur Inc. | 5/22/1953 | 00349281915055 | 2/2/2023 | 49281-0915-68 | False | 00349281915680 | 2/2/2023 | 37 | yellow fever live | PMC | |
49281-0933-50 | FLUZONE High-Dose Quadrivalent Southern Hemisphere | Sanofi Pasteur Inc. | 3/26/2024 | 10/16/2024 | 49281-0933-88 | False | 10/16/2024 | 231 | influenza, Southern Hemisphere, high-dose, quadrivalent | PMC | |||
50090-1502-00 | HAVRIX | A-S Medication Solutions | 8/1/2021 | 3/13/2024 | 50090-1502-09 | False | 2/3/2023 | 52 | Hep A, adult | SKB | |||
50090-1693-09 | IPOL | A-S Medication Solutions | 8/17/2018 | 2/8/2024 | 50090-1693-00 | False | 2/2/2023 | 10 | IPV | PMC | |||
50090-2062-00 | TENIVAC | A-S Medication Solutions | 6/30/2023 | 7/11/2023 | 50090-2062-01 | False | 7/11/2023 | 113 | Td (adult), 5 Lf tetanus toxoid, preservative free, adsorbed | PMC | |||
50090-2883-00 | INFANRIX | A-S Medication Solutions | 9/21/2018 | 1/1/2020 | 1/10/2023 | 50090-2883-09 | False | 1/13/2023 | 20 | DTaP | SKB | ||
50090-3096-00 | RabAvert | A-S Medication Solutions | 8/17/2018 | 1/1/2020 | 1/10/2023 | 58160-0966-01 | False | 3/13/2024 | 176 | Rabies - IM fibroblast culture | SKB | ||
50090-3469-00 | HEPLISAV-B | A-S Medication Solutions | 1/1/2018 | 1/1/2020 | 1/21/2020 | 50090-3469-09 | False | 1/21/2020 | 189 | HepB-CpG | DVX | ||
50090-3781-00 | HAVRIX | A-S Medication Solutions | 7/1/2024 | 7/12/2024 | 50090-3781-01 | False | 7/12/2024 | 83 | Hep A, ped/adol, 2 dose | SKB | |||
50090-4958-01 | GARDASIL 9 | A-S Medication Solutions | 5/22/2023 | 6/6/2023 | 50090-4958-00 | False | 5/25/2023 | 165 | HPV9 | MSD | |||
50090-5147-00 | Shingrix | A-S Medication Solutions | 10/1/2020 | 1/6/2023 | 1/13/2023 | 58160-0828-01 | False | 10358160828017 | 1/17/2024 | 187 | zoster recombinant | SKB | |
50090-6026-00 | PREVNAR 20 | A-S Medication Solutions | 8/10/2021 | 3/1/2024 | 50090-6026-01 | False | 3/1/2024 | 216 | Pneumococcal conjugate PCV20, polysaccharide CRM197 conjugate, adjuvant, PF | PFR | |||
50090-6180-00 | MENQUADFI | A-S Medication Solutions | 5/3/2023 | 5/10/2023 | 50090-6180-01 | False | 2/15/2024 | 203 | meningococcal conjugate quadrivalent, MenACWY-TT (MCV4) | PMC | |||
50090-7036-00 | PNEUMOVAX 23 | A-S Medication Solutions | 3/11/2024 | 3/12/2024 | 50090-7036-01 | False | 3/12/2024 | 33 | pneumococcal polysaccharide PPV23 | MSD | |||
50632-0001-02 | JYNNEOS | Bavarian Nordic A/S | 3/17/2021 | 00350632001020 | 9/26/2024 | 50632-0001-01 | False | 2/1/2023 | 206 | Vaccinia, smallpox Mpox vaccine live, PF, SQ or ID injection | BN | ||
50632-0001-03 | JYNNEOS | Bavarian Nordic A/S | 3/17/2021 | 00350632001037 | 9/26/2024 | 50632-0001-01 | False | 2/1/2023 | 206 | Vaccinia, smallpox Mpox vaccine live, PF, SQ or ID injection | BN | ||
50632-0010-01 | RabAvert | Bavarian Nordic A/S | 5/24/2021 | 2/21/2023 | 50632-0013-01 | False | 2/21/2023 | 176 | Rabies - IM fibroblast culture | BN | |||
50632-0015-02 | Vaxchora | Bavarian Nordic A/S | 6/1/2024 | 00350632015027 | 9/26/2024 | 50632-0015-02 | True | 6/14/2024 | 174 | cholera, live attenuated | BN | ||
50632-0016-02 | Vivotif | Bavarian Nordic A/S | 7/1/2024 | 7/12/2024 | 50632-0016-04 | False | 7/12/2024 | 25 | typhoid, oral | BN | |||
51285-0138-50 | Adenovirus Type 4 and Type 7 Vaccine, Live | Teva Women's Health, Inc. | 5/31/2011 | 7/12/2018 | 51285-0175-02 | False | 1/27/2014 | 143 | Adenovirus types 4 and 7 | BRR | |||
51285-0138-50 | Adenovirus Type 4 and Type 7 Vaccine, Live | Teva Women's Health, Inc. | 5/31/2011 | 7/12/2018 | 51285-0175-02 | False | 1/27/2014 | 143 | Adenovirus types 4 and 7 | TVA | |||
51285-0138-50 | Adenovirus Type 4 and Type 7 Vaccine, Live | Teva Women's Health, Inc. | 5/31/2011 | 7/12/2018 | 51285-0174-02 | False | 1/27/2014 | 143 | Adenovirus types 4 and 7 | BRR | |||
51285-0138-50 | Adenovirus Type 4 and Type 7 Vaccine, Live | Teva Women's Health, Inc. | 5/31/2011 | 7/12/2018 | 51285-0174-02 | False | 1/27/2014 | 143 | Adenovirus types 4 and 7 | TVA | |||
54868-0734-00 | ENGERIX-B | Physicians Total Care, Inc. | 8/5/2002 | 6/30/2012 | 4/6/2018 | 54868-0734-00 | True | 4/6/2018 | 43 | Hep B, adult | SKB | ||
54868-0980-00 | M-M-R II | Physicians Total Care, Inc. | 8/7/1996 | 6/30/2012 | 1/29/2018 | 54868-0980-00 | True | 1/29/2018 | 03 | MMR | MSD | ||
54868-2219-00 | RECOMBIVAX HB | Physicians Total Care, Inc. | 7/23/1986 | 6/30/2012 | 7/13/2018 | 54868-2219-00 | True | 4/6/2018 | 43 | Hep B, adult | MSD | ||
54868-2219-01 | RECOMBIVAX HB | Physicians Total Care, Inc. | 7/23/1986 | 6/30/2012 | 7/13/2018 | 54868-2219-01 | True | 4/6/2018 | 43 | Hep B, adult | MSD | ||
54868-3339-01 | PNEUMOVAX 23 | PHYSICIANS TOTAL CARE, INC | 9/20/1994 | 6/30/2009 | 7/13/2018 | 54868-3339-09 | False | 2/22/2018 | 33 | pneumococcal polysaccharide PPV23 | MSD | ||
54868-4320-00 | PNEUMOVAX 23 | PHYSICIANS TOTAL CARE, INC | 2/20/2006 | 6/30/2011 | 7/13/2018 | 54868-4320-09 | False | 1/27/2014 | 33 | pneumococcal polysaccharide PPV23 | MSD | ||
54868-6177-00 | FLUZONE | PHYSICIANS TOTAL CARE, INC | 9/16/2010 | 6/30/2011 | 4/6/2018 | 54868-6177-00 | True | 4/6/2018 | 141 | Influenza, split virus, trivalent, preservative | PMC | ||
54868-6180-00 | FLUZONE | PHYSICIANS TOTAL CARE, INC | 9/21/2010 | 6/30/2011 | 4/6/2018 | 54868-6180-00 | True | 4/6/2018 | 140 | Influenza, split virus, trivalent, PF | PMC | ||
55045-3841-01 | HAVRIX | Dispensing Solutions, Inc. | 4/13/2007 | 10/4/2019 | 10/15/2019 | 55045-3841-01 | True | 2/5/2021 | 52 | Hep A, adult | SKB | ||
58160-0726-15 | Hiberix | GlaxoSmithKline Biologicals SA | 12/20/2023 | 00358160726156 | 9/19/2024 | 58160-0816-03 | False | 1/25/2024 | 48 | Hib (PRP-T) | SKB | ||
58160-0740-21 | Rotarix | GlaxoSmithKline Biologicals SA | 2/1/2023 | 00358160740213 | 4/24/2023 | 58160-0740-02 | False | 10358160740029 | 4/24/2023 | 119 | rotavirus, monovalent | SKB | |
58160-0801-11 | Menhibrix | GlaxoSmithKline Biologicals SA | 9/3/2013 | 9/17/2017 | 00358160801112 | 5/30/2018 | 58160-0809-01 | False | 00358160809019 | 5/30/2018 | 148 | Meningococcal C/Y-HIB PRP | SKB |
58160-0806-05 | HIBERIX | GlaxoSmithKline Biologicals SA | 8/24/2009 | 12/15/2011 | 6/8/2018 | 58160-0806-01 | False | 00358160806018 | 6/8/2018 | 48 | Hib (PRP-T) | SKB | |
58160-0808-15 | Influenza A (H5N1) Monovalent Vaccine, Adjuvanted | GlaxoSmithKline | 1/18/2018 | 3/27/2023 | 58160-0802-02 | False | 3/23/2023 | 160 | Influenza A monovalent (H5N1), ADJUVANTED-2013 | SKB | |||
58160-0808-15 | Influenza A (H5N1) Monovalent Vaccine, Adjuvanted | GlaxoSmithKline | 1/18/2018 | 3/27/2023 | 58160-0804-01 | False | 3/27/2023 | 160 | Influenza A monovalent (H5N1), ADJUVANTED-2013 | SKB | |||
58160-0809-05 | MENHIBRIX | GlaxoSmithKline Biologicals SA | 9/3/2013 | 9/17/2017 | 5/30/2018 | 58160-0809-01 | False | 00358160809019 | 5/30/2018 | 148 | Meningococcal C/Y-HIB PRP | SKB | |
58160-0810-11 | INFANRIX | GlaxoSmithKline Biologicals SA | 7/24/2009 | 12/14/2022 | 00358160810114 | 12/16/2022 | 58160-0810-01 | False | 10358160810012 | 12/16/2022 | 20 | DTaP | SKB |
58160-0810-52 | INFANRIX | GlaxoSmithKline Biologicals SA | 7/24/2009 | 00358160810527 | 1/31/2022 | 58160-0810-43 | False | 10358160810432 | 2/1/2023 | 20 | DTaP | SKB | |
58160-0811-51 | PEDIARIX | GlaxoSmithKline Biologicals SA | 7/24/2009 | 2/24/2011 | 6/8/2018 | 58160-0811-41 | False | 6/8/2018 | 110 | DTaP-Hep B-IPV | SKB | ||
58160-0811-52 | PEDIARIX | GlaxoSmithKline Biologicals SA | 7/24/2009 | 00358160811524 | 1/31/2022 | 58160-0811-43 | False | 10358160811439 | 2/1/2023 | 110 | DTaP-Hep B-IPV | SKB | |
58160-0812-11 | KINRIX | GlaxoSmithKline Biologicals SA | 7/9/2008 | 6/10/2022 | 00358160812118 | 6/15/2022 | 58160-0812-01 | False | 10358160812016 | 6/14/2022 | 130 | DTaP-IPV | SKB |
58160-0812-52 | KINRIX | GlaxoSmithKline Biologicals SA | 7/9/2008 | 00358160812521 | 1/31/2022 | 58160-0812-43 | False | 10358160812436 | 2/1/2023 | 130 | DTaP-IPV | SKB | |
58160-0815-11 | TWINRIX | GlaxoSmithKline Biologicals SA | 6/7/2007 | 1/18/2018 | 00358160815119 | 5/30/2018 | 58160-0815-01 | False | 00358160815010 | 6/8/2018 | 104 | Hep A-Hep B | SKB |
58160-0815-34 | TWINRIX | GlaxoSmithKline Biologicals SA | 6/7/2007 | 1/18/2018 | 00358160815348 | 5/30/2018 | 58160-0815-05 | False | 00358160815058 | 5/30/2018 | 104 | Hep A-Hep B | SKB |
58160-0815-46 | TWINRIX | GlaxoSmithKline Biologicals SA | 6/7/2007 | 2/3/2011 | 6/8/2018 | 58160-0815-41 | False | 3/23/2023 | 104 | Hep A-Hep B | SKB | ||
58160-0815-48 | TWINRIX | GlaxoSmithKline Biologicals SA | 6/7/2007 | 4/27/2011 | 6/8/2018 | 58160-0815-43 | False | 10358160815437 | 2/13/2024 | 104 | Hep A-Hep B | SKB | |
58160-0815-52 | TWINRIX | GlaxoSmithKline Biologicals SA | 6/7/2007 | 00358160815522 | 2/13/2024 | 58160-0815-43 | False | 10358160815437 | 2/13/2024 | 104 | Hep A-Hep B | SKB | |
58160-0816-05 | Hiberix | GlaxoSmithKline Biologicals SA | 12/21/2015 | 00358160816055 | 7/6/2018 | 58160-0816-01 | False | 10358160816014 | 2/1/2023 | 48 | Hib (PRP-T) | SKB | |
58160-0818-11 | Hiberix | GlaxoSmithKline Biologicals SA | 12/21/2015 | 00358160818110 | 7/6/2018 | 58160-0816-05 | False | 10358160816052 | 5/6/2019 | 48 | Hib (PRP-T) | SKB | |
58160-0819-12 | Shingrix | GlaxoSmithKline Biologicals SA | 10/20/2017 | 00358160819124 | 10/24/2023 | 58160-0828-01 | False | 10358160828017 | 1/17/2024 | 187 | zoster recombinant | SKB | |
58160-0820-11 | ENGERIX-B | GlaxoSmithKline Biologicals SA | 4/25/2007 | 8/30/2019 | 00358160820113 | 9/4/2019 | 58160-0820-01 | False | 10358160820011 | 9/4/2019 | 08 | Hep B, adolescent or pediatric | SKB |
58160-0820-52 | ENGERIX-B | GlaxoSmithKline Biologicals SA | 4/25/2007 | 00358160820526 | 12/7/2017 | 58160-0820-43 | False | 10358160820431 | 2/1/2023 | 08 | Hep B, adolescent or pediatric | SKB | |
58160-0821-11 | ENGERIX-B | GlaxoSmithKline Biologicals SA | 3/28/2007 | 00358160821110 | 12/7/2017 | 58160-0821-01 | False | 10358160821018 | 2/1/2023 | 43 | Hep B, adult | SKB | |
58160-0821-34 | ENGERIX-B | GlaxoSmithKline Biologicals SA | 3/28/2007 | 00358160821349 | 12/7/2017 | 58160-0821-05 | False | 10358160821056 | 2/1/2023 | 43 | Hep B, adult | SKB | |
58160-0821-52 | ENGERIX-B | GlaxoSmithKline Biologicals SA | 3/28/2007 | 00358160821523 | 12/7/2017 | 58160-0821-43 | False | 10358160821438 | 2/1/2023 | 43 | Hep B, adult | SKB | |
58160-0823-11 | Shingrix | GlaxoSmithKline Biologicals SA | 10/20/2017 | 00358160823114 | 10/8/2019 | 58160-0828-03 | False | 10358160828031 | 2/21/2023 | 187 | zoster recombinant | SKB | |
58160-0824-15 | Priorix | GlaxoSmithKline Biologicals SA | 6/3/2022 | 00358160824159 | 10/17/2022 | 58160-0831-03 | False | 10358160831031 | 10/17/2022 | 03 | MMR | SKB | |
58160-0825-11 | HAVRIX | GlaxoSmithKline Biologicals SA | 2/16/2007 | 2/11/2021 | 00358160825118 | 4/5/2021 | 58160-0825-01 | False | 10358160825016 | 3/23/2021 | 83 | Hep A, ped/adol, 2 dose | SKB |
58160-0825-52 | HAVRIX | GlaxoSmithKline Biologicals SA | 2/16/2007 | 00358160825521 | 12/7/2017 | 58160-0825-43 | False | 10358160825436 | 2/1/2023 | 83 | Hep A, ped/adol, 2 dose | SKB | |
58160-0826-11 | HAVRIX | GlaxoSmithKline Biologicals SA | 4/13/2007 | 2/11/2021 | 00358160826115 | 4/5/2021 | 58160-0826-01 | False | 10358160826013 | 3/23/2021 | 52 | Hep A, adult | SKB |
58160-0826-34 | HAVRIX | GlaxoSmithKline Biologicals SA | 4/13/2007 | 3/3/2020 | 00358160826344 | 3/11/2020 | 58160-0826-05 | False | 10358160826051 | 3/11/2020 | 52 | Hep A, adult | SKB |
58160-0826-52 | HAVRIX | GlaxoSmithKline Biologicals SA | 4/13/2007 | 00358160826528 | 12/7/2017 | 58160-0826-43 | False | 10358160826433 | 2/1/2023 | 52 | Hep A, adult | SKB | |
58160-0827-30 | Menveo | GlaxoSmithKline Biologicals SA | 12/9/2022 | 00358160827303 | 4/24/2023 | 58160-0827-03 | False | 10358160827034 | 5/12/2023 | 136 | Meningococcal MCV4O | SKB | |
58160-0830-34 | CERVARIX | GlaxoSmithKline Biologicals SA | 10/16/2009 | 11/29/2016 | 00358160830341 | 5/30/2018 | 58160-0830-05 | False | 5/30/2018 | 118 | HPV, bivalent | SKB | |
58160-0830-52 | CERVARIX | GlaxoSmithKline Biologicals SA | 10/16/2009 | 11/29/2016 | 00358160830525 | 5/30/2018 | 58160-0830-43 | False | 00358160830433 | 5/30/2018 | 118 | HPV, bivalent | SKB |
58160-0842-11 | BOOSTRIX | GlaxoSmithKline Biologicals SA | 7/24/2009 | 00358160842115 | 1/31/2022 | 58160-0842-01 | False | 10358160842013 | 2/1/2023 | 115 | Tdap | SKB | |
58160-0842-34 | BOOSTRIX | GlaxoSmithKline Biologicals SA | 7/24/2009 | 10/26/2020 | 00358160842344 | 1/12/2021 | 58160-0842-05 | False | 10358160842051 | 1/19/2023 | 115 | Tdap | SKB |
58160-0842-51 | BOOSTRIX | GlaxoSmithKline Biologicals SA | 7/24/2009 | 6/15/2011 | 00358160842511 | 6/8/2018 | 58160-0842-41 | False | 6/8/2018 | 115 | Tdap | SKB | |
58160-0842-52 | BOOSTRIX | GlaxoSmithKline Biologicals SA | 7/24/2009 | 00358160842528 | 1/31/2022 | 58160-0842-43 | False | 10358160842433 | 2/1/2023 | 115 | Tdap | SKB | |
58160-0848-11 | Arexvy | GlaxoSmithKline Biologicals SA | 5/3/2023 | 00358160848117 | 6/4/2024 | 58160-0723-03 | False | 10358160723039 | 6/4/2024 | 303 | RSV, recombinant, protein subunit RSVpreF, adjuvant reconstituted, 0.5 mL, PF | SKB | |
58160-0854-52 | ROTARIX | GlaxoSmithKline Biologicals SA | 1/13/2011 | 00358160854521 | 1/2/2024 | 58160-0851-01 | False | 10358160851015 | 1/2/2024 | 119 | rotavirus, monovalent | SKB | |
58160-0855-19 | AS03 | GlaxoSmithKline Biologicals SA | 11/10/2020 | 1/8/2024 | 00358160855191 | 3/12/2024 | 58160-0855-01 | False | 10358160855013 | 2/21/2024 | 801 | AS03 Adjuvant | SKB |
58160-0879-52 | FLUARIX | GlaxoSmithKline Biologicals SA | 7/20/2012 | 6/30/2013 | 12/7/2017 | 58160-0879-41 | False | 11/20/2017 | 140 | Influenza, split virus, trivalent, PF | SKB | ||
58160-0880-52 | FLUARIX | GlaxoSmithKline Biologicals SA | 7/1/2013 | 6/30/2014 | 12/7/2017 | 58160-0880-41 | False | 11/20/2017 | 140 | Influenza, split virus, trivalent, PF | SKB | ||
58160-0881-52 | FLUARIX | GlaxoSmithKline Biologicals SA | 6/27/2014 | 6/30/2015 | 00358160881527 | 5/30/2018 | 58160-0881-41 | False | 00358160881411 | 5/30/2018 | 140 | Influenza, split virus, trivalent, PF | SKB |
58160-0883-52 | FLUARIX | GlaxoSmithKline Biologicals SA | 8/3/2015 | 8/4/2015 | 5/30/2018 | 58160-0883-41 | False | 00358160883415 | 5/30/2018 | 140 | Influenza, split virus, trivalent, PF | SKB | |
58160-0884-52 | FLUARIX | GlaxoSmithKline Biologicals SA | 7/1/2024 | 7/18/2024 | 58160-0884-41 | False | 7/23/2024 | 140 | Influenza, split virus, trivalent, PF | SKB | |||
58160-0885-52 | FLUARIX QUADRIVALENT | GlaxoSmithKline Biologicals SA | 7/2/2020 | 6/30/2021 | 7/18/2024 | 58160-0885-41 | False | 7/18/2024 | 150 | Influenza, split virus, quadrivalent, PF | SKB | ||
58160-0887-52 | FLUARIX QUADRIVALENT | GlaxoSmithKline Biologicals SA | 7/2/2021 | 6/30/2022 | 00358160887529 | 7/18/2024 | 58160-0887-41 | False | 10358160887410 | 7/18/2024 | 150 | Influenza, split virus, quadrivalent, PF | SKB |
58160-0890-52 | FLUARIX QUADRIVALENT | GlaxoSmithKline Biologicals SA | 7/1/2022 | 6/30/2023 | 00358160890529 | 7/18/2024 | 58160-0890-41 | False | 10358160890410 | 7/18/2024 | 150 | Influenza, split virus, quadrivalent, PF | SKB |
58160-0896-52 | FLUARIX QUADRIVALENT | GlaxoSmithKline Biologicals SA | 7/2/2019 | 6/30/2020 | 7/18/2024 | 58160-0896-41 | False | 7/18/2024 | 150 | Influenza, split virus, quadrivalent, PF | SKB | ||
58160-0898-52 | FLUARIX QUADRIVALENT | GlaxoSmithKline Biologicals SA | 6/29/2018 | 6/30/2019 | 00358160898525 | 7/16/2019 | 58160-0898-41 | False | 10358160898416 | 7/16/2019 | 150 | Influenza, split virus, quadrivalent, PF | SKB |
58160-0900-52 | FLUARIX QUADRIVALENT | GlaxoSmithKline Biologicals SA | 7/1/2013 | 6/30/2014 | 12/7/2017 | 58160-0900-41 | False | 11/20/2017 | 150 | Influenza, split virus, quadrivalent, PF | SKB | ||
58160-0901-52 | FLUARIX QUADRIVALENT | GlaxoSmithKline Biologicals SA | 7/1/2014 | 6/30/2015 | 00358160901522 | 5/30/2018 | 58160-0901-41 | False | 00358160901416 | 5/30/2018 | 150 | Influenza, split virus, quadrivalent, PF | SKB |
58160-0903-52 | FLUARIX QUADRIVALENT | GlaxoSmithKline Biologicals SA | 7/1/2015 | 6/30/2016 | 5/30/2018 | 58160-0903-41 | False | 00358160903410 | 5/30/2018 | 150 | Influenza, split virus, quadrivalent, PF | SKB | |
58160-0905-52 | FLUARIX QUADRIVALENT | GlaxoSmithKline Biologicals SA | 7/1/2016 | 6/30/2017 | 7/11/2018 | 58160-0905-41 | False | 7/5/2018 | 150 | Influenza, split virus, quadrivalent, PF | SKB | ||
58160-0907-52 | FLUARIX QUADRIVALENT | GlaxoSmithKline Biologicals SA | 7/7/2017 | 6/30/2018 | 7/9/2018 | 58160-0907-41 | False | 7/9/2018 | 150 | Influenza, split virus, quadrivalent, PF | SKB | ||
58160-0909-52 | FLUARIX QUADRIVALENT | GlaxoSmithKline Biologicals SA | 6/30/2023 | 6/30/2024 | 7/18/2024 | 58160-0909-41 | False | 7/23/2024 | 150 | Influenza, split virus, quadrivalent, PF | SKB | ||
58160-0955-09 | Menveo | GlaxoSmithKline Biologicals SA | 3/1/2017 | 00358160955099 | 12/16/2022 | 58160-0958-01 | False | 10358160958011 | 12/16/2022 | 136 | Meningococcal MCV4O | SKB | |
58160-0955-09 | Menveo | GlaxoSmithKline Biologicals SA | 3/1/2017 | 00358160955099 | 12/16/2022 | 58160-0959-01 | False | 10358160959018 | 12/16/2022 | 136 | Meningococcal MCV4O | SKB | |
58160-0964-12 | RabAvert | GlaxoSmithKline Biologicals SA | 12/19/2016 | 1/31/2024 | 00358160964121 | 3/13/2024 | 58160-0966-01 | False | 3/13/2024 | 176 | Rabies - IM fibroblast culture | SKB | |
58160-0964-12 | RabAvert | GlaxoSmithKline Biologicals SA | 12/19/2016 | 1/31/2024 | 00358160964121 | 3/13/2024 | 58160-0966-12 | False | 7/13/2018 | 176 | Rabies - IM fibroblast culture | SKB | |
58160-0976-06 | Bexsero | GlaxoSmithKline Biologicals SA | 12/1/2016 | 12/31/2021 | 00358160976063 | 1/10/2022 | 58160-0976-02 | False | 10358160976022 | 2/1/2023 | 163 | meningococcal B, OMV | SKB |
58160-0976-20 | Bexsero | GlaxoSmithKline Biologicals SA | 12/1/2016 | 00358160976209 | 1/31/2022 | 58160-0976-02 | False | 10358160976022 | 2/1/2023 | 163 | meningococcal B, OMV | SKB | |
59267-0078-04 | Pfizer-BioNTech Covid-19 Vaccine | Pfizer Manufacturing Belgium NV | 6/17/2022 | 4/18/2023 | 5/3/2023 | 59267-0078-01 | False | 1/17/2024 | 219 | COVID-19, mRNA, LNP-S, PF, 3 mcg/0.2 mL dose, tris-sucrose | PFR | ||
59267-0304-02 | Pfizer-BioNTech Covid-19 Vaccine, Bivalent | Pfizer Manufacturing Belgium NV | 9/1/2022 | 9/11/2023 | 10/26/2023 | 59267-0304-01 | False | 10/26/2023 | 300 | COVID-19, mRNA, LNP-S, bivalent, PF, 30 mcg/0.3 mL dose | PFR | ||
59267-0565-02 | Pfizer-BioNTech Covid-19 Vaccine, Bivalent | Pfizer Manufacturing Belgium NV | 10/12/2022 | 9/11/2023 | 10/26/2023 | 59267-0565-01 | False | 10/26/2023 | 301 | COVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL dose | PFR | ||
59267-0609-02 | Pfizer-BioNTech Covid-19 Vaccine, Bivalent | Pfizer Manufacturing Belgium NV | 12/9/2022 | 9/11/2023 | 10/26/2023 | 59267-0609-01 | False | 10/26/2023 | 302 | COVID-19, mRNA, LNP-S, bivalent, PF, 3 mcg/0.2 mL dose | PFR | ||
59267-1000-02 | Pfizer-BioNTech Covid-19 Vaccine | Pfizer Manufacturing Belgium NV | 12/12/2020 | 4/18/2023 | 5/3/2023 | 59267-1000-01 | False | 5/3/2023 | 208 | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose | PFR | ||
59267-1000-03 | Pfizer-BioNTech Covid-19 Vaccine | Pfizer Manufacturing Belgium NV | 12/12/2020 | 4/18/2023 | 5/3/2023 | 59267-1000-01 | False | 5/3/2023 | 208 | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose | PFR | ||
59267-1025-02 | Pfizer-BioNTech Covid-19 Vaccine | Pfizer Manufacturing Belgium NV | 10/1/2021 | 11/1/2021 | 11/9/2021 | 59267-1025-01 | False | 5/3/2023 | 217 | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose | PFR | ||
59267-1025-03 | Pfizer-BioNTech Covid-19 Vaccine | Pfizer Manufacturing Belgium NV | 10/1/2021 | 4/18/2023 | 5/3/2023 | 59267-1025-01 | False | 5/3/2023 | 217 | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose | PFR | ||
59267-1025-04 | Pfizer-BioNTech Covid-19 Vaccine | Pfizer Manufacturing Belgium NV | 10/1/2021 | 4/18/2023 | 5/3/2023 | 59267-1025-01 | False | 5/3/2023 | 217 | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose | PFR | ||
59267-1055-02 | Pfizer-BioNTech Covid-19 Vaccine | Pfizer Manufacturing Belgium NV | 10/1/2021 | 11/1/2021 | 11/9/2021 | 59267-1055-01 | False | 5/3/2023 | 218 | COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose | PFR | ||
59267-1055-04 | Pfizer-BioNTech Covid-19 Vaccine | Pfizer Manufacturing Belgium NV | 10/1/2021 | 4/18/2023 | 5/3/2023 | 59267-1055-01 | False | 5/3/2023 | 218 | COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose | PFR | ||
59267-1404-02 | Pfizer-BioNTech Covid-19 Vaccine, Bivalent | Pfizer Manufacturing Belgium NV | 9/1/2022 | 9/11/2023 | 10/26/2023 | 59267-1404-01 | False | 10/26/2023 | 300 | COVID-19, mRNA, LNP-S, bivalent, PF, 30 mcg/0.3 mL dose | PFR | ||
59267-4315-02 | Pfizer-BioNTech Covid-19 Vaccine | Pfizer Manufacturing Belgium NV | 9/11/2023 | 7/31/2024 | 00359267431523 | 9/19/2024 | 59267-4315-01 | False | 10359267431513 | 9/19/2024 | 308 | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 3 mcg/0.3 mL | PFR |
59267-4331-02 | Pfizer-BioNTech Covid-19 Vaccine | Pfizer Manufacturing Belgium NV | 9/11/2023 | 8/31/2024 | 00359267433121 | 9/19/2024 | 59267-4331-01 | False | 10359267433111 | 9/19/2024 | 310 | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 10 mcg/0.3 mL | PFR |
59267-4426-02 | Pfizer-BioNTech Covid-19 Vaccine | Pfizer Manufacturing Belgium NV | 8/22/2024 | 8/30/2024 | 59267-4426-01 | False | 8/30/2024 | 308 | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 3 mcg/0.3 mL | PFR | |||
59267-4438-02 | Pfizer-BioNTech Covid-19 Vaccine | Pfizer Manufacturing Belgium NV | 8/22/2024 | 8/30/2024 | 59267-4438-01 | False | 8/30/2024 | 310 | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 10 mcg/0.3 mL | PFR | |||
59676-0580-15 | Janssen COVID-19 Vaccine | Janssen Products, LP | 2/1/2021 | 6/20/2023 | 7/11/2023 | 59676-0580-05 | False | 7/10/2023 | 212 | COVID-19 vaccine, vector-nr, rS-Ad26, PF, 0.5 mL | JSN | ||
62195-0051-01 | Ixiaro | Vetter Pharma Fertigung GmbH & Co. KG | 11/23/2020 | 12/29/2020 | 62195-0051-01 | True | 6/15/2018 | 134 | Japanese Encephalitis IM | VAL | |||
62195-0051-10 | Ixiaro | Vetter Pharma Fertigung GmbH & Co. KG | 3/30/2009 | 11/23/2020 | 12/29/2020 | 62195-0051-01 | False | 6/15/2018 | 134 | Japanese Encephalitis IM | VAL | ||
62577-0613-01 | Flucelvax | Novartis Vaccines and Diagnostics, Inc. | 7/1/2014 | 6/30/2015 | 5/30/2018 | 62577-0613-11 | False | 5/30/2018 | 153 | Influenza, MDCK, trivalent, PF | NOV | ||
62577-0614-01 | Flucelvax | Novartis Vaccines and Diagnostics, Inc. | 7/1/2014 | 6/30/2016 | 7/6/2018 | 62577-0614-11 | False | 7/5/2018 | 153 | Influenza, MDCK, trivalent, PF | NOV | ||
63361-0243-10 | VAXELIS | MSP Vaccine Company | 4/10/2020 | 00363361243104 | 9/19/2024 | 63361-0243-58 | False | 00363361243586 | 9/19/2024 | 146 | DTaP,IPV,Hib,HepB | MSP | |
63361-0243-15 | VAXELIS | MSP Vaccine Company | 10/1/2020 | 00363361243159 | 9/19/2024 | 63361-0243-88 | False | 00363361243883 | 9/19/2024 | 146 | DTaP,IPV,Hib,HepB | MSP | |
63361-0245-10 | VAXELIS | MCM Vaccine Co. | 12/21/2018 | 4/10/2020 | 4/21/2020 | 63361-0245-58 | False | 9/19/2024 | 146 | DTaP,IPV,Hib,HepB | PMC | ||
63851-0501-01 | RabAvert | Novartis Vaccines and Diagnostics GmbH | 10/20/1997 | 1/19/2017 | 6/8/2018 | 63851-0511-11 | False | 00363851511119 | 4/15/2020 | 176 | Rabies - IM fibroblast culture | NOV | |
63851-0501-02 | RabAvert | GSK Vaccines GmbH | 7/8/2014 | 3/31/2020 | 00363851501028 | 4/16/2020 | 63851-0511-11 | False | 00363851511119 | 4/15/2020 | 176 | Rabies - IM fibroblast culture | NOV |
63851-0612-01 | Flucelvax | Novartis Vaccines and Diagnostics GmbH | 8/30/2013 | 6/30/2014 | 5/30/2018 | 63851-0612-11 | False | 5/30/2018 | 153 | Influenza, MDCK, trivalent, PF | NOV | ||
63851-0613-01 | FLUCELVAX | Novartis Vaccines and Diagnostics GmbH | 7/1/2014 | 6/30/2015 | 5/30/2018 | 63851-0613-11 | False | 5/30/2018 | 153 | Influenza, MDCK, trivalent, PF | NOV | ||
64678-0211-01 | BioThrax | Emergent BioDefense Operations Lansing, LLC | 11/4/1970 | 12/7/2017 | 64678-0211-05 | False | 2/1/2023 | 24 | Anthrax, pre-exposure prophylaxis, post-exposure prophylaxis | MIP | |||
66019-0107-01 | FLUMIST | MedImmune, LLC | 7/17/2009 | 4/19/2010 | 7/13/2018 | 66019-0107-01 | True | 2/13/2018 | 111 | Influenza, live, trivalent, intranasal | MED | ||
66019-0108-10 | FLUMIST | MedImmune, LLC | 7/22/2010 | 6/30/2011 | 7/13/2018 | 66019-0108-01 | False | 1/29/2018 | 111 | Influenza, live, trivalent, intranasal | MED | ||
66019-0109-10 | FLUMIST | MedImmune, LLC | 6/30/2011 | 7/19/2012 | 7/13/2018 | 66019-0109-01 | False | 1/29/2018 | 111 | Influenza, live, trivalent, intranasal | MED | ||
66019-0110-10 | FluMist | MedImmune, LLC | 8/1/2012 | 7/18/2013 | 7/13/2018 | 66019-0110-01 | False | 11/20/2017 | 111 | Influenza, live, trivalent, intranasal | MED | ||
66019-0200-10 | Influenza A H1N1 Intranasal | MedImmune, LLC | 10/1/2009 | 4/13/2010 | 7/13/2018 | 66019-0200-01 | False | 1/29/2018 | 125 | Novel Influenza-H1N1-09, nasal | MED | ||
66019-0300-10 | FluMist Quadrivalent | MedImmune, LLC | 7/15/2013 | 6/30/2014 | 7/13/2018 | 66019-0300-01 | False | 5/30/2018 | 149 | Influenza, live, quadrivalent, intranasal | MED | ||
66019-0301-10 | FluMist Quadrivalent | MedImmune, LLC | 7/1/2014 | 6/30/2015 | 7/12/2018 | 66019-0301-01 | False | 5/30/2018 | 149 | Influenza, live, quadrivalent, intranasal | MED | ||
66019-0302-10 | FluMist Quadrivalent | MedImmune, LLC | 7/15/2013 | 6/30/2016 | 7/13/2018 | 66019-0302-01 | False | 5/30/2018 | 149 | Influenza, live, quadrivalent, intranasal | MED | ||
66019-0303-10 | FluMist Quadrivalent | MedImmune, LLC | 7/25/2016 | 6/30/2017 | 7/12/2018 | 66019-0303-01 | False | 5/30/2018 | 149 | Influenza, live, quadrivalent, intranasal | MED | ||
66019-0304-10 | FluMist Quadrivalent | MedImmune, LLC | 8/25/2017 | 6/30/2018 | 8/20/2018 | 66019-0304-01 | False | 8/20/2018 | 149 | Influenza, live, quadrivalent, intranasal | MED | ||
66019-0305-10 | FluMist Quadrivalent | MedImmune, LLC | 8/10/2018 | 4/30/2019 | 5/21/2019 | 66019-0305-01 | False | 5/21/2019 | 149 | Influenza, live, quadrivalent, intranasal | MED | ||
66019-0306-10 | FluMist Quadrivalent | MedImmune, LLC | 9/5/2019 | 3/6/2020 | 7/18/2024 | 66019-0306-01 | False | 7/18/2024 | 149 | Influenza, live, quadrivalent, intranasal | MED | ||
66019-0307-10 | FluMist Quadrivalent | MedImmune, LLC | 8/10/2020 | 4/1/2021 | 7/18/2024 | 66019-0307-01 | False | 7/18/2024 | 149 | Influenza, live, quadrivalent, intranasal | MED | ||
66019-0308-10 | FluMist Quadrivalent | MedImmune, LLC | 8/2/2021 | 3/15/2022 | 00366019308101 | 7/18/2024 | 66019-0308-01 | False | 7/18/2024 | 149 | Influenza, live, quadrivalent, intranasal | MED | |
66019-0309-10 | FluMist Quadrivalent | MedImmune, LLC | 8/8/2022 | 3/15/2023 | 7/18/2024 | 66019-0309-01 | False | 7/18/2024 | 149 | Influenza, live, quadrivalent, intranasal | MED | ||
66019-0310-10 | FluMist Quadrivalent | MedImmune, LLC | 8/14/2023 | 8/5/2024 | 9/17/2024 | 66019-0310-01 | False | 9/17/2024 | 149 | Influenza, live, quadrivalent, intranasal | MED | ||
66019-0311-10 | FluMist | MedImmune, LLC | 8/6/2024 | 9/3/2024 | 66019-0311-00 | False | 8/28/2024 | 111 | Influenza, live, trivalent, intranasal | MED | |||
66521-0000-01 | FLUAD | Novartis Vaccines and Diagnostics Limited | 11/24/2015 | 6/30/2016 | 8/13/2018 | 66521-0000-11 | False | 7/9/2018 | 168 | Influenza, adjuvanted, trivalent, PF | NOV | ||
66521-0112-02 | Fluvirin | Novartis Vaccines and Diagnostics Ltd | 8/12/1998 | 6/30/2010 | 5/30/2018 | 66521-0112-02 | True | 7/5/2018 | 140 | Influenza, split virus, trivalent, PF | NOV | ||
66521-0112-10 | Fluvirin | Novartis Vaccines and Diagnostics Ltd | 8/12/1998 | 6/30/2010 | 5/30/2018 | 66521-0112-10 | True | 7/5/2018 | 141 | Influenza, split virus, trivalent, preservative | NOV | ||
66521-0113-02 | FLUVIRIN | Novartis Vaccines and Diagnostics Limited | 8/12/1988 | 6/30/2011 | 5/30/2018 | 66521-0113-02 | True | 7/5/2018 | 140 | Influenza, split virus, trivalent, PF | NOV | ||
66521-0113-10 | FLUVIRIN | Novartis Vaccines and Diagnostics Limited | 8/12/1988 | 6/30/2011 | 5/30/2018 | 66521-0113-10 | True | 7/5/2018 | 141 | Influenza, split virus, trivalent, preservative | NOV | ||
66521-0114-02 | FLUVIRIN | Novartis Vaccines and Diagnostics Limited | 7/1/2011 | 6/30/2012 | 5/30/2018 | 66521-0114-02 | True | 4/23/2020 | 140 | Influenza, split virus, trivalent, PF | NOV | ||
66521-0114-10 | FLUVIRIN | Novartis Vaccines and Diagnostics Limited | 7/1/2011 | 6/30/2012 | 5/30/2018 | 66521-0114-10 | True | 5/30/2018 | 141 | Influenza, split virus, trivalent, preservative | NOV | ||
66521-0115-02 | FLUVIRIN | Novartis Vaccines and Diagnostics Limited | 7/20/2012 | 6/30/2013 | 5/30/2018 | 66521-0115-02 | True | 00366521115020 | 7/5/2018 | 140 | Influenza, split virus, trivalent, PF | NOV | |
66521-0115-10 | FLUVIRIN | Novartis Vaccines and Diagnostics Limited | 7/20/2012 | 6/30/2013 | 5/30/2018 | 66521-0115-10 | True | 7/5/2018 | 141 | Influenza, split virus, trivalent, preservative | NOV | ||
66521-0116-02 | Fluvirin | Novartis Vaccines and Diagnostics Limited | 7/30/2013 | 6/30/2014 | 3/5/2018 | 66521-0116-12 | False | 11/20/2017 | 140 | Influenza, split virus, trivalent, PF | NOV | ||
66521-0116-10 | Fluvirin | Novartis Vaccines and Diagnostics Limited | 7/30/2013 | 6/30/2014 | 12/7/2017 | 66521-0116-11 | False | 11/20/2017 | 141 | Influenza, split virus, trivalent, preservative | NOV | ||
66521-0117-02 | Fluvirin | Novartis Vaccines and Diagnostics Ltd | 7/1/2014 | 6/30/2015 | 7/6/2018 | 66521-0117-12 | False | 7/5/2018 | 140 | Influenza, split virus, trivalent, PF | NOV | ||
66521-0117-10 | Fluvirin | Novartis Vaccines and Diagnostics Ltd | 7/1/2014 | 6/30/2015 | 7/6/2018 | 66521-0117-11 | False | 00366521117116 | 7/5/2018 | 141 | Influenza, split virus, trivalent, preservative | NOV | |
66521-0118-02 | Fluvirin | Novartis Vaccines and Diagnostics Limited | 7/1/2015 | 6/30/2016 | 7/11/2018 | 66521-0118-12 | False | 7/9/2018 | 140 | Influenza, split virus, trivalent, PF | NOV | ||
66521-0118-10 | Fluvirin | Novartis Vaccines and Diagnostics Limited | 7/1/2015 | 6/30/2016 | 7/11/2018 | 66521-0118-11 | False | 7/9/2018 | 141 | Influenza, split virus, trivalent, preservative | NOV | ||
66521-0200-02 | Influenza A (H1N1) 2009 Monovalent Vaccine | Novartis Vaccines and Diagnostics Ltd | 9/15/2009 | 6/30/2010 | 10/15/2019 | 66521-0200-02 | True | 10/15/2019 | 127 | Novel influenza-H1N1-09 | NOV | ||
66521-0200-10 | Influenza A (H1N1) 2009 Monovalent Vaccine | Novartis Vaccines and Diagnostics Ltd | 9/15/2009 | 6/30/2010 | 10/15/2019 | 66521-0200-10 | True | 10/15/2019 | 126 | Novel influenza-H1N1-09, preservative-free | NOV | ||
69401-0000-02 | Vivotif | Emergent Travel Health Inc. | 3/16/1992 | 00369401000027 | 10/9/2024 | 69401-0000-01 | False | 2/1/2023 | 25 | typhoid, oral | PAX | ||
70460-0001-01 | Vaxchora | Paxvax, Inc. | 10/3/2016 | 8/1/2021 | 8/16/2021 | 70460-0002-02 | False | 8/16/2021 | 174 | cholera, live attenuated | PAX | ||
70460-0004-01 | Vaxchora | Emergent Travel Health Inc. | 9/15/2019 | 00370460004017 | 9/26/2024 | 70460-0002-02 | False | 8/16/2021 | 174 | cholera, live attenuated | PAX | ||
70461-0001-01 | FLUAD | Seqirus, Inc. | 7/1/2016 | 6/30/2017 | 7/12/2018 | 70461-0001-11 | False | 7/5/2018 | 168 | Influenza, adjuvanted, trivalent, PF | SEQ | ||
70461-0002-01 | FLUAD | Seqirus Inc. | 7/1/2017 | 6/30/2018 | 7/9/2018 | 70461-0002-11 | False | 7/9/2018 | 168 | Influenza, adjuvanted, trivalent, PF | SEQ | ||
70461-0018-03 | FLUAD | Seqirus, Inc. | 7/13/2018 | 7/31/2019 | 8/22/2019 | 70461-0018-04 | False | 8/15/2019 | 168 | Influenza, adjuvanted, trivalent, PF | SEQ | ||
70461-0019-03 | FLUAD | Seqirus, Inc. | 8/1/2019 | 6/30/2020 | 00370461019034 | 7/18/2024 | 70461-0019-04 | False | 00370461019041 | 7/18/2024 | 168 | Influenza, adjuvanted, trivalent, PF | SEQ |
70461-0020-03 | FLUAD | Seqirus, Inc. | 7/1/2020 | 7/31/2021 | 7/18/2024 | 70461-0020-04 | False | 7/18/2024 | 168 | Influenza, adjuvanted, trivalent, PF | SEQ | ||
70461-0024-03 | FLUAD | Seqirus, Inc. | 7/1/2024 | 00370461024038 | 9/27/2024 | 70461-0024-04 | False | 00370461024045 | 9/27/2024 | 168 | Influenza, adjuvanted, trivalent, PF | SEQ | |
70461-0119-02 | Fluvirin | Seqirus, Inc. | 7/1/2016 | 6/30/2017 | 7/12/2018 | 70461-0119-12 | False | 5/30/2018 | 140 | Influenza, split virus, trivalent, PF | SEQ | ||
70461-0119-10 | Fluvirin | Seqirus, Inc. | 7/1/2016 | 6/30/2017 | 7/12/2018 | 70461-0119-11 | False | 5/30/2018 | 141 | Influenza, split virus, trivalent, preservative | SEQ | ||
70461-0120-02 | Fluvirin | Seqirus Inc. | 7/1/2017 | 6/30/2018 | 7/9/2018 | 70461-0120-12 | False | 7/9/2018 | 140 | Influenza, split virus, trivalent, PF | SEQ | ||
70461-0120-03 | FLUAD QUADRIVALENT | Seqirus, Inc. | 7/1/2020 | 6/30/2021 | 7/18/2024 | 70461-0120-04 | False | 7/18/2024 | 205 | Influenza, adjuvanted, quadrivalent, PF | SEQ | ||
70461-0120-10 | Fluvirin | Seqirus Inc. | 7/1/2017 | 6/30/2018 | 7/9/2018 | 70461-0120-11 | False | 7/9/2018 | 141 | Influenza, split virus, trivalent, preservative | SEQ | ||
70461-0121-03 | FLUAD QUADRIVALENT | Seqirus, Inc. | 7/1/2021 | 6/30/2022 | 7/18/2024 | 70461-0121-04 | False | 7/18/2024 | 205 | Influenza, adjuvanted, quadrivalent, PF | SEQ | ||
70461-0122-03 | FLUAD QUADRIVALENT | Seqirus, Inc. | 7/1/2022 | 7/31/2023 | 00370461122031 | 7/18/2024 | 70461-0122-04 | False | 00370461122048 | 7/18/2024 | 205 | Influenza, adjuvanted, quadrivalent, PF | SEQ |
70461-0123-03 | FLUAD QUADRIVALENT | Seqirus, Inc. | 7/1/2023 | 6/30/2024 | 00370461123038 | 8/6/2024 | 70461-0123-04 | False | 00370461123045 | 8/6/2024 | 205 | Influenza, adjuvanted, quadrivalent, PF | SEQ |
70461-0200-01 | FLUCELVAX QUADRIVALENT | Seqirus, Inc. | 7/1/2016 | 6/30/2017 | 7/13/2018 | 70461-0200-11 | False | 7/5/2018 | 171 | Influenza, MDCK, quadrivalent, PF | SEQ | ||
70461-0201-01 | FLUCELVAX QUADRIVALENT (PREFILLED SYRINGE) | Seqirus, Inc. | 7/1/2017 | 6/30/2018 | 7/9/2018 | 70461-0201-11 | False | 7/9/2018 | 171 | Influenza, MDCK, quadrivalent, PF | SEQ | ||
70461-0301-10 | FLUCELVAX QUADRIVALENT (MULTI-DOSE VIAL) | Seqirus, Inc. | 7/1/2017 | 6/30/2018 | 7/9/2018 | 70461-0301-12 | False | 7/9/2018 | 186 | Influenza, MDCK, quadrivalent, preservative | SEQ | ||
70461-0318-03 | FLUCELVAX QUADRIVALENT (PREFILLED SYRINGE) | Seqirus, Inc. | 7/1/2018 | 7/31/2019 | 1/23/2020 | 70461-0318-04 | False | 8/22/2019 | 171 | Influenza, MDCK, quadrivalent, PF | SEQ | ||
70461-0319-03 | FLUCELVAX QUADRIVALENT | Seqirus, Inc. | 7/30/2019 | 7/31/2020 | 00370461319035 | 7/18/2024 | 70461-0319-04 | False | 00370461319042 | 7/18/2024 | 171 | Influenza, MDCK, quadrivalent, PF | SEQ |
70461-0320-03 | FLUCELVAX QUADRIVALENT | Seqirus Inc. | 7/2/2020 | 7/1/2021 | 7/18/2024 | 70461-0320-04 | False | 7/18/2024 | 171 | Influenza, MDCK, quadrivalent, PF | SEQ | ||
70461-0321-03 | FLUCELVAX QUADRIVALENT | Seqirus Inc. | 7/1/2021 | 6/30/2022 | 7/18/2024 | 70461-0321-04 | False | 7/18/2024 | 171 | Influenza, MDCK, quadrivalent, PF | SEQ | ||
70461-0322-03 | Flucelvax Quadrivalent | Seqirus Inc. | 7/1/2022 | 6/30/2023 | 00370461322035 | 7/18/2024 | 70461-0322-04 | False | 00370461322042 | 7/18/2024 | 171 | Influenza, MDCK, quadrivalent, PF | SEQ |
70461-0323-03 | Flucelvax Quadrivalent | Seqirus Inc. | 7/1/2023 | 6/30/2024 | 8/6/2024 | 70461-0323-04 | False | 00370461323049 | 8/6/2024 | 171 | Influenza, MDCK, quadrivalent, PF | SEQ | |
70461-0418-10 | FLUCELVAX QUADRIVALENT (MULTI-DOSE VIAL) | Seqirus, Inc. | 7/1/2018 | 7/31/2019 | 8/22/2019 | 70461-0418-11 | False | 8/22/2019 | 186 | Influenza, MDCK, quadrivalent, preservative | SEQ | ||
70461-0419-10 | FLUCELVAX QUADRIVALENT | Seqirus, Inc. | 7/30/2019 | 7/31/2020 | 00370461419100 | 7/18/2024 | 70461-0419-11 | False | 00370461419117 | 7/18/2024 | 186 | Influenza, MDCK, quadrivalent, preservative | SEQ |
70461-0420-10 | FLUCELVAX QUADRIVALENT | Seqirus Inc. | 7/2/2020 | 7/1/2021 | 7/18/2024 | 70461-0420-11 | False | 7/18/2024 | 186 | Influenza, MDCK, quadrivalent, preservative | SEQ | ||
70461-0421-10 | FLUCELVAX QUADRIVALENT | Seqirus Inc. | 7/2/2021 | 6/30/2022 | 7/18/2024 | 70461-0421-11 | False | 7/18/2024 | 186 | Influenza, MDCK, quadrivalent, preservative | SEQ | ||
70461-0422-10 | Flucelvax Quadrivalent | Seqirus Inc. | 7/1/2022 | 6/30/2023 | 00370461422100 | 7/18/2024 | 70461-0422-11 | False | 00370461422117 | 7/18/2024 | 186 | Influenza, MDCK, quadrivalent, preservative | SEQ |
70461-0423-10 | Flucelvax Quadrivalent | Seqirus Inc. | 7/1/2023 | 6/30/2024 | 00370461423107 | 8/6/2024 | 70461-0423-11 | False | 00370461423114 | 8/6/2024 | 186 | Influenza, MDCK, quadrivalent, preservative | SEQ |
70461-0554-10 | Flucelvax | Seqirus Inc. | 7/1/2024 | 00370461554108 | 9/27/2024 | 70461-0554-11 | False | 00370461554115 | 9/27/2024 | 320 | Influenza, MDCK, trivalent, preservative | SEQ | |
70461-0654-03 | Flucelvax | Seqirus Inc. | 7/1/2024 | 00370461654037 | 9/27/2024 | 70461-0654-04 | False | 00370461654044 | 9/27/2024 | 153 | Influenza, MDCK, trivalent, PF | SEQ | |
71665-0001-02 | CYFENDUS | Emergent Product Development Gaithersburg Inc. | 9/19/2023 | 6/11/2024 | 71665-0001-01 | False | 1/25/2024 | 318 | Anthrax, post-exposure prophylaxis | MIP | |||
71665-0330-02 | ACAM2000 | Emergent Product Development Gaithersburg Inc. | 8/31/2007 | 6/15/2022 | 71665-0330-01 | False | 2/1/2023 | 75 | vaccinia (smallpox) | MIP | |||
75052-0001-10 | PREHEVBRIO | VBI Vaccines (Delaware) Inc. | 12/1/2021 | 3/1/2024 | 75052-0001-01 | False | 3/1/2024 | 220 | HepB recombinant, 3-antigen, Al(OH)3 | VBI | |||
76420-0482-01 | Medical Provider Single Use EZ Flu Shot 2013-2014 | MedChem Manufacturing Inc. dba Enovachem | 5/30/2013 | 6/30/2014 | 7/13/2018 | 76420-0482-01 | True | 5/30/2018 | 150 | Influenza, split virus, quadrivalent, PF | PMC | ||
76420-0483-01 | Medical Provider Single Use EZ Flu Shot 2013-2014 | MedChem Manufacturing Inc. dba Enovachem | 5/30/2013 | 6/30/2014 | 7/13/2018 | 76420-0483-01 | True | 5/30/2018 | 150 | Influenza, split virus, quadrivalent, PF | PMC | ||
80631-0100-10 | NOVAVAX COVID-19 Vaccine, Adjuvanted | Novavax, Inc. | 3/1/2022 | 10/3/2023 | 7/29/2024 | 80631-0100-01 | False | 7/29/2024 | 211 | COVID-19, subunit, rS-nanoparticle+Matrix-M1 Adjuvant, PF, 0.5 mL | NVX | ||
80631-0102-10 | NOVAVAX COVID-19 Vaccine, Adjuvanted | Novavax, Inc. | 2/1/2023 | 10/3/2023 | 7/29/2024 | 80631-0102-01 | False | 7/29/2024 | 211 | COVID-19, subunit, rS-nanoparticle+Matrix-M1 Adjuvant, PF, 0.5 mL | NVX | ||
80631-0105-02 | NOVAVAX COVID-19 Vaccine, Adjuvanted | Novavax, Inc. | 9/1/2023 | 7/29/2024 | 8/6/2024 | 80631-0105-01 | False | 8/6/2024 | 313 | COVID-19, subunit, rS-nanoparticle, adjuvanted, PF, 5 mcg/0.5 mL | NVX | ||
80631-0107-10 | NOVAVAX COVID-19 VACCINE, ADJUVANTED | Novavax, Inc. | 8/30/2024 | 9/9/2024 | 80631-0107-01 | False | 9/9/2024 | 313 | COVID-19, subunit, rS-nanoparticle, adjuvanted, PF, 5 mcg/0.5 mL | NVX | |||
80777-0100-99 | Spikevax | Moderna US, Inc. | 6/1/2022 | 4/18/2023 | 10/24/2023 | 80777-0100-11 | False | 10/24/2023 | 207 | COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose | MOD | ||
80777-0102-93 | Spikevax | Moderna US, Inc. | 9/11/2023 | 8/21/2024 | 00380777102931 | 9/24/2024 | 80777-0102-01 | False | 00380777102016 | 9/24/2024 | 312 | COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL | MOD |
80777-0102-95 | Spikevax | Moderna US, Inc. | 9/11/2023 | 8/21/2024 | 00380777102955 | 9/24/2024 | 80777-0102-04 | False | 00380777102047 | 9/24/2024 | 312 | COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL | MOD |
80777-0102-96 | Spikevax | Moderna US, Inc. | 9/11/2023 | 8/21/2024 | 00380777102962 | 9/24/2024 | 80777-0102-01 | False | 00380777102016 | 9/24/2024 | 312 | COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL | MOD |
80777-0110-93 | Spikevax | Moderna US, Inc. | 8/22/2024 | 00380777110936 | 9/26/2024 | 80777-0110-01 | False | 00380777110011 | 9/26/2024 | 312 | COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL | MOD | |
80777-0110-96 | Spikevax | Moderna US, Inc. | 8/22/2024 | 00380777110967 | 9/26/2024 | 80777-0110-01 | False | 00380777110011 | 9/26/2024 | 312 | COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL | MOD | |
80777-0273-98 | Moderna COVID-19 Vaccine | Moderna US, Inc. | 4/1/2021 | 4/18/2023 | 5/30/2023 | 80777-0273-15 | False | 5/30/2023 | 207 | COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose | MOD | ||
80777-0273-99 | Moderna COVID-19 Vaccine | Moderna US, Inc. | 12/18/2020 | 4/18/2023 | 5/30/2023 | 80777-0273-10 | False | 5/30/2023 | 207 | COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose | MOD | ||
80777-0275-99 | Moderna COVID-19 Vaccine | Moderna US, Inc. | 3/29/2022 | 4/18/2023 | 5/30/2023 | 80777-0275-05 | False | 5/30/2023 | 221 | COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL dose | MOD | ||
80777-0277-99 | Moderna COVID-19 Vaccine | Moderna US, Inc. | 6/1/2022 | 6/1/2022 | 5/30/2023 | 80777-0277-05 | False | 5/30/2023 | 227 | COVID-19, mRNA, LNP-S, PF, pediatric 50 mcg/0.5 mL dose | MOD | ||
80777-0279-99 | Moderna COVID-19 Vaccine | Moderna US, Inc. | 6/1/2022 | 4/18/2023 | 5/30/2023 | 80777-0279-05 | False | 5/30/2023 | 228 | COVID-19, mRNA, LNP-S, PF, pediatric 25 mcg/0.25 mL dose | MOD | ||
80777-0282-99 | Moderna COVID-19 Vaccine, Bivalent | Moderna US, Inc. | 7/28/2022 | 9/11/2023 | 10/26/2023 | 80777-0282-05 | False | 10/26/2023 | 229 | COVID-19, mRNA, LNP-S, bivalent, PF, 50 mcg/0.5 mL or 25mcg/0.25 mL dose | MOD | ||
80777-0283-99 | Moderna COVID-19 Vaccine, Bivalent | Moderna US, Inc. | 9/23/2022 | 9/11/2023 | 10/26/2023 | 80777-0283-02 | False | 10/26/2023 | 230 | COVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL | MOD | ||
80777-0287-92 | Moderna COVID-19 Vaccine | Moderna US, Inc. | 9/11/2023 | 8/21/2024 | 8/30/2024 | 80777-0287-07 | False | 8/30/2024 | 311 | COVID-19, mRNA, LNP-S, PF, 25 mcg/0.25 mL | MOD | ||
80777-0291-80 | Moderna COVID-19 Vaccine | Moderna US, Inc. | 8/22/2024 | 00380777291802 | 9/26/2024 | 80777-0291-09 | False | 00380777291093 | 9/26/2024 | 311 | COVID-19, mRNA, LNP-S, PF, 25 mcg/0.25 mL | MOD | |
80777-0291-81 | Moderna COVID-19 Vaccine | Moderna US, Inc. | 8/22/2024 | 8/30/2024 | 80777-0291-09 | False | 00380777291093 | 9/26/2024 | 311 | COVID-19, mRNA, LNP-S, PF, 25 mcg/0.25 mL | MOD | ||
80777-0345-90 | mRESVIA | Moderna US, INC. | 5/31/2024 | 6/11/2024 | 80777-0345-01 | False | 6/11/2024 | 326 | RSV, mRNA, injectable, PF | MOD | |||
80777-0345-96 | mRESVIA | Moderna US, INC. | 5/31/2024 | 6/11/2024 | 80777-0345-01 | False | 6/11/2024 | 326 | RSV, mRNA, injectable, PF | MOD |
Column Definitions
Sale NDC11: NDC11 for the unit of sale
Sale Proprietary Name: Proprietary name of the unit of sale
Sale Labeler: Name of the labeler
Sale Start Date: Date product began to be marketed
Sale End Date: Date product was no longer marketed
Sale GTIN: GTIN barcode for unit of sale
Sale Last update: Date the unit of sale record was last updated
Use NDC11: NDC11 for unit of use
No Use NDC: Indicator if unit of sale has NDC. If TRUE, the unit of use NDC is set to match unit of sale NDC.
Use GTIN: GTIN barcode for unit of use
Use Last update: Date the unit of use record was last updated
CVX: CVX code for product
CVX Name: Vaccine name from CVX table